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ABSTRACT
The Effects of Vitamin B6 Supplementation
on Premenstrual Symptoms

February, 1985

Kim Elizabeth Kendall, B.A.
M.

S.

,

,

University of California/Davis

University of Massachusetts

Ph.D., University of Massachusetts

Directed by:

Professor Bonnie Strickland

A double-blind controlled study of the effects of vitamin B6
supplementation on premenstrual symptoms was conducted.

Fifty-six women

who reported moderate to severe premenstrual mood changes participated in
the study.

Symptoms were monitored prospectively through daily home

recordkeeping over a one month baseline period and
ment period (3 months total).

a two month treat-

Subjects received daily supplements of

150 mg of vitamin B6 or the equivalent of a placebo over the entire two

month treatment period.

Analysis of covariance and t-test comparison

symptoms
results suggested that vitamin B6 may improve some premenstrual

(including dysphoria) during periods of increased stress.

Vitamin B6 was

subjective ratings of
observed to have a general ability to improve
phase.
concentration level regardless of menstrual cycle

Data also sugges

be more effective than vitamin
ted that a placebo in capsule form may

premenstrual symptoms.
B6 in tablet form in ameliorating
are discussed.
of inquiry and methodological concerns
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CHAPTER

I

INTRODUCTION

For centuries the monthly hormonal cycling in women has been

associated with fluctuations in physical and psychological well-being.

Through the ages, the effects of menstrual changes have variously
influenced women in their cultures and legends.

In this century,

scientific documentation of these phenomena has begun to accumulate.
For many women the monthly changes are associated with serious

difficulties.

Recent reviews have cited the increased incidence of

psychiatric problems such as suicidal behavior and rate of hospitalizations
for women during the premenstrum (Abramowitz and Balar, 1982; Berlin,

Bergey and Money, 1982; Dalton, 1959; Jacobs and Charles, 1970; Smith,
1975;

Steiner and Carroll, 1977), as well as increased criminal acts

(Dalton, 1980).

Although for most women, premenstrual symptoms do not

require professional intervention, epidemiological evidence suggests
that from 70% to 90% of all women report recurrent premenstural symptoms,
mental
and 20% to 40% of women experience some degree of temporary
Yen, 1981).
or physical dysfunction premenstrually (Reid and

premenstrual syndrome is widely variable among women.

The

Some women become

and lethargic.
tense and irritable, while others feel depressed

Physical

swelling and tendersymptoms may include headache, backache, fatigue,
changes in appetite, migraine,
ness of breast or abdominal tissues,

1
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acne, seizures, and hypoglycemia (Smith,

1975; Reid and Yen,

1981).

The relationship between physical and psychological symptoms has yet
to be clarified; however,

some researchers have recently attempted to

identify symptom patterns or clusters, combining both physical and

psychological symptoms (Endicott, Halbreich, Schacht and Nee, 1981;
Haskett, Steiner, Osmun and Carroll, 1980; Moos, 1968).
A variety of pituitary, adrenal, and ovarian hormones

excessive or insufficient levels, or in improper balance

— at either
— have been

implicated as possible causes of premenstrual disturbances.

Estrogen,

progesterone, follicle stimulating hormone, luteinizing hormone, prolactin, ACTH, Cortisol, and monoamine oxidase all show periodic changes in

blood level in relation to the menstrual cycle.

Renin, angiotensin, and

aldosterone, which regulate body fluid blance, also fluctuate cyclically (Steiner and Carroll, 1977).

The elimination of ovarian cyclicity

through the administration of an agonist of gonadotropin-releasing
hormone was shown to markedly reduce physical and behavioral premenstrual
symptoms in a double-blind crossover study involving eight subjects

diagnosed as having PMS (Muse, Cetel, Futterman and Yen, 1984).

Neverthe-

been found
less, no identifiable endocrine or physiologic markers have

without (Reid and Yen,
to distinguish women with the syndrome from those
1981).

psychological factors
It is also clear that social, cultural, and

stress, and life style
such as attitudes, expectancies, vulnerability to
into account in any
choice are salient factors which must be taken
(Sherif, 1980).
comprehensive investigation of this problem

3

While interrelated functioning of many of these substances has
been
documented in laboratory studies, the central mechanism leading to the
premenstrual syndrome continues to elude researchers.
s

Accumulated

research evidence suggests that this syndrome is related to a

dysfunction along the hypothalamic-pituitary-ovarian axis (Reid and
Yen,

1981).

It seems possible that in such a complex system of

interacting substances and processes, the variety of premenstrual
symptoms could result from any number of possible systemic imbalances,

rather than from a single consistent underlying cause.

Because of the immediacy of the problem of widespread and debilitating premenstrual distress, it has been for many researchers and

clinicians at least as important to discover means to alleviate symptoms,
as it has been to identify underlying causes.

Given the enormous

complexity and variety of causal patterns suggested by the accumulated
research, it is understandable that fruitful investigations of

appropriate treatments have been extremely difficult to accomplish.
Careful examination of the literature shows it to be
inadequate.

f rustratingly

Many popular remedies for menstrual and premenstrual

distress have been untested or have been based on evidence from poorly

controlled or uncontrolled clinical trials (Smith, 1975).

Yet, vast

physicians, subject
numbers of women, with the collaboration of their

which may
themselves to chemical remedies of unknown effectiveness
have serious side effects.

Oral contraceptives, progesterone, and

used treatments, but the
diuretic agents are three of the most widely
in which these have been
few well-controlled, double-blind studies

A

studied, have failed to demonstrate their effectiveness (Steiner
and

Carroll, 1977).

The possible risks of increased cancer and circulatory

disorders suspected with the use of synthetic hormones are well known.

Diuretics can have a variety of side effects, including depression
(Huapaya and Ananth, 1980)
the premenstrual syndrome.

—

one of the major symptoms associated with

Given these cautions, it is of particular

importance to delineate treatments that are both safe and effective.
One of the main goals of this research was to develop a general

methodology suitable for studying the menstrual cycle, to begin the
delineation of particular variables that warrant further research,
and to develop a rigorously controlled method for testing alternative treatments for various premenstrual symptoms.

Nutritional treatments have become increasingly popular, as
growing number of women prefer to avoid the use of drugs.

a

Currently,

there is no way for these women to make informed decisions regarding
the effectiveness of nutritional treatments.

Although it seems logical

that some form of dietary supplementation might ameliorate premenstrual

symptoms without the danger of side effects, very little controlled

research has been done to test its effectiveness.

Perhaps the most

involves
popular vitamin therapy for the premenstural syndrome currently

dietary supplements of pyridoxine (vitamin B6)

.

The purpose of this

vitamin B6
research was to determine whether dietary supplements of

depression and irritability
can exert a beneficial effect on premenstrual
in particular.

addressed later
The rationale for this treatment will be

in this paper.

review of
The following is intended to be a brief
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major research directions regarding the premenstrual syndrome.

Overview of Regulation of the Menstrual Cycle
The brain controls the interacting activities of the hypothalamus,

pituitary, and ovaries, thereby controlling release of hormones.

The

ovaries provide feedback signals to the brain-pituitary system which,
in turn, responds by adjusting the amount and type of hormone to be

released.

Most menstrual disorders are commonly due to disturbances in

the brain-pituitary portion of this regulatory system.

An understand-

ing of these interacting components is necessary in order to examine

physiological and psychological factors that may be involved in the
premenstural syndrome.

This section is intended to summarize, in a

general way, the physiological processes which regulate

a

normal

menstrual cycle.
The average menstrual cycle lasts 28 days and begins on the first
day of menses (period of menstrual bleeding)

.

The first half of a

the
cycle is the follicular phase, and the luteal phase makes up

second half.

The follicular and luteal phases are divided by ovulation

and again
which occurs at midcycle, or approximately at day number 14,

are divided by the onset of the menses.

The first half of the follicular

of this phase begins on
phase includes the menses and the second half

(Yen, 1981).
the 6th or 7th day of the menstrual cycle

Other authors

luteal phase into the early
have chosen to further subdivide the

periods (Rossi and Rossi,
luteal phase, late luteal, and premenstrual
these
25-28, respectively comprising
1980); days 17-21, 22-2A, and

subdivisions

6

During the early follicular phase, the hypothalamus signals the

pituitary which, in turn, releases follicle stimulating hormone (FSH)
FSH encourages the follicles in the ovaries to begin to grow and

mature and produce estrogen.

The second half of the follicular phase

is marked by an increase in the release of estradiol and esterone.

Estradiol rises slowly at first, and then rapidly to a peak, stimulating
the release of

luteinizing hormone (LH) by the pituitary.

One day

later, a peak surge of LH is seen which stimulates the rupture of a

follicle and the release of an ovum (egg).

As estrogen levels rise,

Several days before the surge of LH

FHS levels decrease.

,

levels of

androgens, testosterone and progesterone are also beginning to rise
due to increased activity in the follicles.

Ovulation is accompanied

by an abrupt surge in LH-FSH, which lasts about 36 hours, followed by

release of the ovum 24 hours later.

Once the ovum is released, LH

continues to influence the follicle to become the progesterone producing
corpus luteum (yellow body).
levels fall abruptly.

Progesterone levels rise and estrogen

Progesterone produced by the corpus luteum

of
stimulates the lining of the uterus to prepare for the implantation

Peak progesterone

the ovum which is on its way via the fallopian tubes.

levels are reached about

8

days after the LH surge.

smaller increases are seen in

17

* -hydroxyprogesterone

esterone, while LH and FSH continue to decline.
a lifetime of about

14 days.

Parallel, but
,

estradiol, and

The corpus luteum has

(Interestingly, both estrogen and proges-

to destroy this same
terone produced by the luteal tissue seem

tissue, forming a self-destruct mechanism.)

If the ovum is not

fertilized, or it is fertilized too late for it to develop sufficiently
by the time it reaches the uterus, it is unable to implant itself in
the

lining of the uterus, leading to a decline in progesterone and

decline in estrogen in the late luteal phase.

a

further

This decline may initiate

local production of prostaglandins, which are thought to promote

vasoconstriction, as well as other factors involved in the process of
sloughing off and expelling the lining of the uterus.

At the end of the

luteal phase, or the beginning of the menses, FHS levels begin to rise
again to initiate the growth of the follicles for the next cycle
(Carlson, 1977; Yen, 1981).

Other factors have been linked to the premenstrual syndrome, because
they also fluctuate over the menstrual cycle.

Cortisol levels are higher
Aldosterone (an

during the follicular phase than the luteal phase.

electrolyte-regulating hormone of the adrenal cortex) is two times
higher during the luteal phase than the follicular phase, peaking the
9th or 10th day before menses and dropping rapidly

6

or

days before

Corticosterone

menstrual bleeding begins (Steiner and Carroll, 1977).
and desoxycorticosterone show a similar pattern.

7

Progesterones and

estrogens induce the formation of angiotensin which initiates and
parallels fluctuations in levels of aldosterone (Steiner and Carroll,
1977)

.

these factors
It has been hypothesized that one or several of

imbalance and
related to the normal menstrual cycle may be an

syndrome (IMS)
may be responsible for the premenstrual

.

,

therefore,

The following

8

is intended to be a review of the major theories of dysfunction which

physiologists have explored in relationship to the PMS

Estrogen Excess - Progesterone Deficiency
Since 1931, it has been proposed that an excess of estrogen might
be responsible for the PMS.

More recently, reports have documented

increased levels of estrogen and decreased levels of progesterone on

women with the PMS (Backstrom and Carstensen, 1974; Munday
Taylor, 1977, 1981).

,

Brush and

Unbalanced estrogen production could be

responsible for fluid retention, breast swelling, abdominal swelling,
abnormal carbohydrate metabolism, as well. as mood changes seen in
the PMS.

Other studies have found that levels of estrogen and proges-

terone withdrawal, not an improper estrogen :progesterone ratio, might
be responsible for the PMS (Kutger and Brown, 1972).

Although it was

thought that the administration of natural or synthetic progesterones

might, therefore, alleviate the PMS, there have been no large

double-blind studies demonstrating the usefulness of either progesterone
Smith,
or testosterone therapy in treating the PMS (Reid and Yen, 1981;
1975)

.

popular in
Treatment of the PMS with progesterone is still fairly

clinics (Reid and Yen, 1981).

Indirect evidence for the possible

on oral
effectiveness of progesterone therapy came with research

which were highly
contraceptives which showed that contraceptives
and those that were strongly
estrogenic made premenstrual symptoms worse

progesterogenic improved premenstrual dysphoria.

Oral contraceptives

9

were reported to both lessen and worsen premenstrual symptoms.

Controlled studies by Coppen
(see Steiner and Carroll,

Milne, Outram and Weber and by Jordheim

,

1977)

failed to confirm the effectiveness of

oral contraceptives in treating the PMS

Synthetic progesterones

,

when studied in a controlled manner,

do not seem to be more effective in treating the PMS than a placebo

(Jordheim, 1972; Reid and Yen

,

1981; Sampson,

1979): Swyer,

1955).

Again, however, uncontrolled studies continue to support the notion
that progesterone treatment can be useful (Berlin, Bergey and Money,
1982; Dalton,

1980; Kerr, Day, Munday

,

Brush, Watson and Taylor, 1980).

It is interesting that several of these authors (Munday, Brush

and Taylor, 1981) later reverse themselves and conclude that it is

unlikely that progesterone plays an important role in the PMS, since
the greatest progesterone deficit occurs at the mid-luteal phase
(days 8 to

9

premenstrually) before symptoms are most severe.

They

also feel that the estrogenrprogesterone ratio does not appear to differ

markedly in the PMS

,

but suggest that there does appear to be a large

difference in estrogen levels at the time of most severe symptoms
(days

1

to 4 premenstrually)

.

High premenstrual levels of estrogen

and
have also been cited as a possible factor in the PMS by Backstrom

Carstensen (1981).
concentrations.
Estrogen is known to affect neurotransmitter

norepinephrine
High estrogens are usually associated with low

concentrations (La Torre, 1974).

It is possible that estrogen could

on
affect behavior in different ways depending

the levels of progester one

10

present (Munday, Brush and Taylor, 1981).

Low levels of estrogen are

known to correlate with high levels of monoamine oxidase
which, in
turn, may deplete catecholamines (Abramowitz, Baker and
Fleischer,
1982; La Torre,

1974).

This evidence, along with research which has

shown that oral contraceptives are associated with increased levels
of premenstrual depression,

in the PMS

,

suggest that estrogens may have a role

and one that is more important than the role progesterone

may play (Smith, 1975).
Aside from the effects that estrogen and progesterone may have on

catecholamine levels and subsequent changes in mood, both estrogen
and progesterone are thought to affect changes in fluid retention which

occur premenstrually

.

Estrogen may be involved in premenstrual fluid

retention by increasing synthesis and activity of plasma renin and

angiotensin II.

Renin and angiotensin II are known to raise blood

pressure through vasoconstriction.

They also increase the output of

aldosterone, a hormone which affects the fluid and electrolyte balance
of the body (Reid and Yen,

1981)

.

Progesterone may also have a role

in modulating fluid retention and blood pressure, again by affecting

the activity of plasma renin and the secretion of aldosterone.

It has

been suggested that in this case, progesterone and not estrogen is
primarily responsible for the rise in renin and aldosterone seen during
the luteal (premenstrual) phase (Reid and Yen, 1981).

1

Aldosterone, Vasopressin and Angiotensin
In normal and PMS women, aldosterone levels are similar.
it seems that

However,

women with the PMS may excrete larger quantities of

aldosterone than controls.

It is possible that increased secretion

of aldosterone might result from stress and/or decreased dopamine

activity levels (Reid and Yen, 1981).

But, a recent report by

Munday, Brush and Taylor (1981) found that there were no differences

between PMS women and controls in aldosterone levels.

This finding has

been supported by studies which have shown that lowering aldosterone
levels by administering spirolactone (an aldosterone antagonist)

was no more effective than placebo in alleviating premenstrual symptoms
(Smith,

1975).

Like aldosterone, vasopressin, another component of the

renin-angiotensin system which is released by the pituitary, constricts
blood vessels and raises blood pressure.

vasopressin release.

Estrogen may regulate

Evidence has linked vasopressin to water retention

seen premenstrually and there are some reports, from inadequately

controlled studies, showing the effectiveness of vasopressin antagonists
on PMS symptoms (Reid and Yen, 1981).

Steiner and Carroll (1977) feel that the renin-angiotensin system
is not likely to be involved in the PMS.

The fact that aldosterone

suggests that
activity levels drop six days before menstruation begins,
it

to dysphoria and water
is not likely that aldosterone is related

retention seen in the late luteal phase.

This notion is further

renin-angiotensin system do
substantiated by reports that changes in the

12

not occur in anovulatory cycles.

Premenstrual depression and

dysphoria, however, do occur in anovulatory cycles,
suggesting that

angiotensin is not responsible for mood changes seen
premenstrually
(Steiner and Carroll, 1977).

It is interesting to note that proges-

terone levels also do not fluctuate in anovulatory cycles, again

suggesting that progesterone does not play a role in premenstrual

dysphoria (Adamopoulos
and Carroll,

1977)

,

Loraine

,

Lunn, Coppen and Daly, 1972; Steiner

.

Prolactin
Prolactin has complex influences on gonadal functions and is
responsible for initiating lactation and promoting the growth of
breast tissue.

Levels of prolactin (PRL) fluctuate with the menstrual

cycle, having higher levels during the luteal phase than the follicular, with peak levels occurring at ovulation.

It also seems that

PRL levels can vary greatly from woman to woman and from day to day
(Reid and Yen,

1982; Steiner and Carroll,

1977).

PRL levels remain

elevated during the late luteal phase, while levels of estrogen and
progesterone are dropping.

High levels of PRL are thought to inhibit

ovulation, and at the time of Steiner and Carroll's review (1977),
several authors had found abnormally high levels of PRL in women

with premenstrual tension.

More recent studies reviewed by Reid and

Yen (1981) have failed to confirm this finding.

Several researchers

which
have tried to treat the PMS with bromocriptine, a substance
contradictory results
suppresses the release of PRL by the pituitary, and

have been found.

1

!

Rein and Yen argue that although most researchers in
this area
assume that PRL is responsible for fluid retention and
that it is,
therefore, responsible for premenstrual fluid retention (as well
as

perhaps other premenstrual symptoms)

,

it has not been established that

PRL has osmoregulatory effects in humans.

These authors suggest that

PRL may indirectly affect the PMS by increasing dopamine activity,
which in turn might improve moods or reverse water retention.

Reid

and Yen (1981) were, nevertheless, unable to conclude that PRL per se
is an important factor in premenstrual tension.

De La Fuente and Rosenbaum (1981), based on Steiner and Carroll's
1977 review, proposed that excess levels of PRL may interact with

ovarian hormones to produce premenstrual symptoms featured by depression

when estrogen is low, and featured by irritability-hostility when

progesterone levels are low.

They support this hypothesis with the

finding that postpartum depression usually occurs at a time when PRL
levels are above normal and estrogen and progesterone levels have
dropped.

It seems, though,

that these authors did not have access to

the more recent findings reviewed by Reid and Yen which suggest that

PRL is not involved in the PMS.
A more recent study, not mentioned in the review by Reid and Yen,
also supports the view that PRL is not a major factor in the PMS.
levels
Backstrom and Aavaag (1981), in earlier work, had found lowered

with the PMS.
of progesterone during the luteal phase in women

They

progesterone might be
had hypothesized that these lowered levels of
is thought to influen
explained by fluctuations in PRL, since this hormone

14

steroid hormone production and can cause the corpus luteum to
produce

insufficient amounts of progesterone.

Fifteen women diagnosed

as having the PMS were compared to 17 controls.

The mean PRL levels

for the PMS group was not significantly different from that of

controls, even when those women with less severe PMS were excluded
and when possible effects of sampling time were analyzed.

Again, it

seems that PRL does not, in itself, play a major role in the PMS.

Endorphins and MSH

Endogenous (within the body) opiate receptors have recently
been discovered and may be involved in many central nervous system
(CNS)

disorders.

Halbreigh and Endicott (1981) have hypothesized

that decreases in endorphins may be involved in premenstrual depression,

while an increase may contribute to anxious-agitated premenstrual
depression.

High levels of endorphins occur during pregnancy and

after birth and, therefore, may be involved in postpartum depression.
Since endorphins, like exogenous (external) opiates have an euphoric
effect, it has been proposed that endorphins may be involved in mania
and depression.

Endorphins may also affect dopamine and serotonin

levels associated with depression directly, or indirectly by inhancing
,

dopamine turnover.

Drugs such as naloxone and naltrexone, which

increased
block the activity of endorphins, can induce symptoms of

together clinically,
sexual desire and dysphoria which are rarely seen
but have been reported together premenstrually

15

Prolactin levels may be higher in women with premenstrual
tension
(see above) and since dopamine inhibits the release of prolactin,

elevated prolactin may indicate decreased dopamine activity.
Endorphins may also affect prolactin levels directly, since all
opiates are known to stimulate prolactin.

Opiates interact with norepinephrine, serotonin and acetylcholine,

increasing their synthesis.

Serotonin is thought to be related to

changes in depression, irritability, pain sensitivity and sexual desire,

which are changes frequently seen during the premenstrtnr
and Endicott,

1981)

(Halbreich

.

Reid and Yen (1981) have also hypothesized a role for endorphins
in the PMS and have reviewed other research which may link endorphins
to this syndrome.

Endorphins have an antidiuretic effect, increasing

the release of vasopressin (known to regulate fluid retention and modu-

late other pituitary functions)

.

Endogenous opiates also affect

glucose metabolism (blood sugar levels) by eliciting the release of

glucagon and insulin, resulting in hyperglycemia (high blood sugar)
in humans and secondary hyperinsulism (chronically elevated levels of

insulin)

.

Disturbances in glucose metabolism have been found

premenstrually

,

particularly hypoglycemic (low blood sugar) conditions,

which could be caused by withdrawal of opiates (Reid and Yen, 1981).
Opiates inhibit appetite and thirst.
of prostaglandin E x

.

the small intestines.

They may also inhibit the action

Prostaglandin Ej stimulates fluid secretion

in

Inhibition of this action may result in consti-

pation often associated with opiates.

The analgesic effects of opiates

16

involve cyclic adenosine monophosphate which is stimulated by

prostaglandins.

Changes in appetite, pain sensitivity, constipation

and diarrhea are fairly common premenstrual symptoms.

Like Halbreich and Endicott (1981), Reid and Yen (1981) postulate
an abberant release of, or sensitivity to endorphins in the PMS

Additionally, they hypothesize that melanocy te-stimulating hormone
(MSH) may also be involved in the PMS.

This hormone is known to

increase awareness of environmental stimuli and enhance arousal and
attention.

The fact that MSH, like the endorphins, is influenced

by sex hormones and influences pituitary activity makes it a likely

candidate for a role in the PMS as well.

Melanocyte-stimulating hormone (MSH) is

a

peptide from the

anterior pituitary that influences the deposition of pigment in the
body.

Sex hormones appear to have a role in the regulation of synthesis

and release of MSH, estrogen promotes its synthesis, but inhibits its

release, while progesterone enhances release of MSH.

In humans,

MSH influences adaptive behavior through its ability to enhance arousal
and attention and to increase awareness of environmental stimuli.

Even,

though there is not direct evidence for MSH having a role in the PMS,
stimulate
the fact that it is known to affect arousal and attention, to

known to act
levels of growth hormone, LH and FSH in humans, and it is

modulate mood, behavior,
in concert with endorphins, suggests that MSH may
endorphins (Reid and Yep,
and functioning of the pituitary along with
1981)
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Endorphin-induced inhibition of central biogenic amine
systems (norepinephrine, serotonin and dopamine) may
produce mood changes, increased appetite and thirst.
Mastodynia (breast swelling), fluid retention, constipation, and abdominal bloating in individual cases
may result from endorphin incited increases in the
levels of prolactin and vasopressin and the inhibitory
effect of endorphins on prolactin action within the
bowel (constipation). Withdrawal of endogenous opiate
stimulus affords relief from these complaints, but may
trigger new symptoms. Increased activity of biogenic
amine systems may produce rapid improvement in mood
and relief from mastodynia, edema and bloating. Release
from opiate inhibition of prostaglandin action may
explain headaches and loose stool which frequently
accompany the onset of menstruation. In exceptional
cases, an excessive rebound to dopaminergic hyperf unction
may explain the development of late premenstrual hyperactivity, irritability, aggressive and hostile behavior,
or psychosis .. .Differing amounts of gonadal steroid
levels from month to month and from person to person
may account for the heterogeneous and variable clinical
manifestations of this disorder. (Reid and Yen, 1981)

Androgens and Testosterone-Estradiol Binding Globulin

Androgens have been thought to influence sexual desire in women
and both increases and decreases in libido have been noted during

premenstruum.

Backstrom and Aavaag (1981) compared the levels of

testosterone and testosterone-estradiol binding globulin (TeBG) in
15

women diagnosed with PMS and

same age.
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normal controls of approximately the

Diagnosis of PMS was determined based on the development of

mental symptoms regularly every premenstrual week, cessation of the
remainder
symptoms at the start of menstruation, and no symptoms during the
of the cycle.

Mean plasma testogterone levels did not differ significantly

concentrations were
in the PMS group; however, when overall luteal phase
PMS group.
calculated, TeBG binding capacity was higher in the

Because
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active testosterone is thought to be in the unbound
form, higher
levels of TeBG binding capacity suggest an overall
increase in

bound (inactive) testosterone and a decrease in active
(unbound)
testosterone, resulting perhaps in a physiologically less active
supply
of testosterone in spite of the fact that mean testosterone
concen-

trations did not differ between the two groups of women.

Maureen Dalton (1981) also compared levels of TeBG binding capacity
of 50 women with severe PMS and 50 age-matched controls.

She

hypothesized that changes in the binding capacity might be responsible
for changes in total estradiol concentrations which had been previously

reported in the literature.

Her PMS group differed, however, from

other studies; all 50 women had suffered severe premenstrual symptoms

leading to mental hospitalization, suicide attempts, criminal

offenses and premenstrual violence.

Dalton found that the PMS group

had significantly lower TeBG binding capacity in contrast to the

findings of Backstrom and Aavaag (1981).

Like Backstrom and Aavaag,

she also found no differences in total testosterone or estradiol con-

centrations.

She hypothesized that perhaps a defect in the liver

might affect production of TeBG.

Dalton's findings suggest that higher

levels of active or unbound testosterone and estradiol may exist at the

tissue level.

Her findings are more consistent with researchers who

have found high estrogen and low progesterone levels in women with
PMS.

L9

MAO Activity Levels

Another factor which has been implicated in the PMS is
monoamine
oxidase (MAO), an enzyme which catalyzes the formation of
aldehydes,

ammonia and hydrogen peroxide.

Substances which inhibit MAO activity

increase the activity of dopamine, serotonin and norepinephrine in the
brain.

Due to this effect on catecholamines, MAO inhibitors are some-

times used as antidepressants (Miller and Keane, 1978).

levels may be altered in the PMS.

MAO activity

High levels of MAO activity have

been found in premenstrual women and it has been speculated that

progesterone could stimulate MAO activity and be responsible for
the depression seen in some women premenstrually (Abramowitz, Baker

and Fleisher, 1982; Steiner and Carroll, 1977).

Some doubt has been

cast on this hypothesis because other authors have found that MAO

activity levels did not correlate with a global scale of menstrual

mood variations (Steiner and Carroll, 1977).

Vitamin A
The use of vitamin A in the treatment of premenstrual pain was

accidentally discovered in 1947 by Simkins, after having administered
the vitamin to treat hyperthyroidism (Block, 1960).

Carotene is

thought to inactivate thyroxin and, therefore, reduce thyroid hyper-

activity which often exists premenstrually.

It has also been

and,
postulated that vitamin A may inactivate estrogen in the liver

estrogen levels.
in this way, compensate for premenstrual increased
in reducing
Block (1960) reported that vitamin A was most useful

symptoms of headache and tension.

well designed.

Unfortunately, his study was not

vitamin A
Two other reports of the effectiveness of
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have been reviewed by Reid and Yen (1981); however, none
of these
reports have been substantiated and the topic deserves further

exploration.

It is interesting to note that vitamin A intake may

be comprised in a large portion of our population.

Lower income groups

of white and black females are more likely to have vitamin A intake

levels below standard.

It is extimated that between 18-23% of

these women may be below intake norms (NES

,

1971-72).

Data indicate

that vitamin A intake is a major public concern for Spanish-Americans
in low income states (Ten-State Nutrition Survey, 1966-70).

V itamin B6

Reid and Yen (1981) have done the best review of the theoretical

grounds for the use of vitamin B6 (pyridoxine) in the treatment of
the PMS

.

Vitamin B therapy has been advocated since the 1940's.

During this period it was thought that vitamin B-complex deficiency
might lead to an excess of estrogen in the PMS.

Biskind and Biskind

(1943) had noticed that a vitamin B deficiency in rats impaired

estrogen metabolism, while androgens continue to be inactivated,
leading to an imbalance in the estrogen-androgen equilibrium.

They

reported successful treatment of the PMS with vitamin B, as well as
successful treatment of some symptoms of menopause, menorrhagia
(excessive menstruation)

,

cystic mastitis (breast cysts)

,

and

vitamin
metrorrhagia (irregular menses) in women who showed signs of
(fissured and
deficiency, glossitis (inflamed tongue) and cheilosis

B
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scaled lips) were the most common of these symptoms.

Women were fre-

quently treated initially with parental doses of vitamin

B,

rather

than oral therapy, as impaired absorption often occurs in
nutritional

deficiency.

In 1948, during the war, Zondek and Brezezinsky
(1948)

studied 14 women who showed severe signs of vitamin B deficiency and
found no signs of impaired estrogen degradation in these women.

Their

findings diminished the popularity of vitamin B therapy.
Interst in vitamin B therapy revived when it was discovered that
it acts as a coenzyme

(pyridoxal phosphate) in the synthesis of

dopamine and serotonin (Reid and Yen, 1981)

.

Due to this revived

interest and popularization of vitamin megadoses, cases of vitamin B

toxicity have been reported when taken in amounts ranging from

2

to 5

grams per day (Shcaumburg, Kaplan, Windeback, Vick, and Rasmus, 1983;

Pleasure and Bowen, 1983).

Toxic doses of pyridoxine may cause wide-

spread, non-specific axonal degeneration affecting large and small

myelinated fibers and result in impaired sensation, gait and coordination.

These symptoms, in some cases, have only been partially reversible.

An estrogen-induced deficiency of the enzyme pyridoxal phosphate) has

been suggested as a possible factor in depression in women on oral contra-

ceptive and in women with the PMS (Adams, Wynn, Rose, Seed, Folkard and
Strong,

Draper, John1973; Adams, Wynn, Seed and Folkard, 1974; Herzberg,

son and Nicol,

1971; Rose,

1979).

Rose (1978) speculated that estrogen

which compete for
might alter vitamin B6 distribution and induce enzymes

available B6

.

of this
Women on oral contraceptives do show a disturbance

a pyridoxine supplement
meitabolic pathway which can be corrected by
I
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(Winston, 1973).

Because there are many such enzyme reactions

which are pyridoxine dependent, it has been
suggested that a vitamin
B6 deficiency might manifest itself in various
ways clinically and

that depression may be only one manifestation
of such a deficiency

(Winston, 1973).

It is possible that a deficiency of
pyridoxine could

contribute to other symptoms seen with oral contraceptives
and in the
PMS.

Several recent studies have documented an association between

low vitamin B6 serum levels and depression in research comparing

depressed patients with non-depressed patients and controls (Carvey

Williams and Sheffield, 1979; Nobbs, 1974; Russ

Hendricks, Chrisley,

,

Kaliu and Driskell, 1983).

Disturbed glucose levels are observed in women on oral contraceptives (Winston, 1973) and have been reported in women premenstrually

More recent evidence suggests that carbohydrate tolerance is increased

premenstraully and this might account for cravings often reported by
women at this time (Reid and Yen, 1981).

Vitamin B6 supplements have

been shown to improve the impaired glucose tolerance curve seen in

women on oral contraceptives (Winston, 1973)

.

In a well-controlled

study, vitamin B6 supplements were shown to be effective in reducing

premenstrual levels of depression in women on oral contraceptives
(Adams et al.

,

1978)

Three controlled studies have been done examining the possibility
that vitamin B6 supplements might alleviate dysphoria associated

wi th the PMS.

In one study (Stokes and Mendels

,

1972), 13 women with
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PMS, who served as their own controls, were given either
placebo or

vitamin B6 supplements in a double-blind manner.

These authors found

no differences in moods between the vitamin and the placebo
periods
as measured by the Moos menstrual distress questionnaire.

The results

of this study are difficult to evaluate, because full details of

the protocol, subjects, and results have never been published.

Supplements were given monthly for an 18-day period prior to and including
the first few days of the menses and dosages were not specified in this

report, but are likely not to have exceeded 50 mg/day.

Four women

showed a tendancy toward improvement on the vitamin; however, this
result was not significant.

It may be that inadequate dosages were

given or that they were given for too brief a period.

It is also

possible that subtle effects due to vitamin supplementation would
not appear with a sample size of only 13.

Further methodological

issues will be discussed later in this paper.
(1983) used a souble-blind

,

Mattes and Martin

placebo controlled crossover procedure

to evaluate the fffect of 50 mg of pyridoxine given ten days prior to

menstruation on premenstrual depression in three women.

Each

woman reported subjective decreases in premenstrual depression while
and
on vitamin B6 supplementation vs. placebo condition. Abraham

Hargrove (1980) used a similar procedure and demonstrated

a significant

doses of 500 mg
response of carefully defined symptoms to vitamin B6 in

per day compared to placebo.
a small sample size and,

This study, unfortunately, also used

therefore, is difficult to generalize from.

.
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The fact that vitamin B6 plays a role in the synthesis
of dopamine
and serotonin led other researchers to postulate that this
vitamin

might alter prolactin levels, since dopamine and serotonin are involved
in the control of prolactin release.

Serotonin activity has been shown

to facilitate a rise in prolactin, whereas dopamine inhibits this

release (Mcintosh, 1976).

Initial studies showed that vitamin B6

could depress prolactin secretion and, therefore, inhibit lactation
and restore menses in women with amenorrhea (Delitala, Masala, Magna

and Devilla, 1976; Mcintosh, 1976; Reid and Yen, 1981).

Several sub-

sequent studies reviewed by Reid and Yen have failed to demonstrate

similar effects.

These studies make it seem less likely that

vitamin B6 might affect disorders which result from excess prolactin
levels
Again, three studies have assessed the clinical usefulness of

vitamin B6 supplementation for the PMS (Abraham and Hargrove, 1980;
Mattes and Martin, 1983; Stokes and Mendels, 1972).

The possibility

that supplementation may be useful needs further substantiation (Reid

and Yen, 1981).

This is especially true in light of recent evidence

which suggests that a significant portion of Americans might be
vitamin B deficient.

Deficiencies of pyridoxine, thiamin, and ribofla-

vin (B vitamins) often occur hand-in-hand.

It is difficult to estimate

signs of overall
their rate of occurrence separately; however, clinical

vitamin

B

of
deficiency can be observed in a substantial portion

(NES
children and adults (2-18%) in the United States

,

1971-72).

s
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Lithium
Treatment of the PMS with lithium has been explored due
to the
cyclic nature of the syndrome and symptoms of depression
which commonly
exist.

In these ways, the PMS resembled psychiatric
disturbances

for which lithium is the treatment of choice (Steiner and
Carroll,

1977).

Steiner and Carroll (1977) have carefully reviewed the

research in this area and the later review by Reid and Yen (1981) does
not include more recent work regarding the use of lithium to treat
the PMS.

Several researchers in the late 60

's

and early 70

good effect of lithium in treating the PMS.

's

reported a

In 1974, two controlled

studies by Singer, Cheng and Schou (1974) and Mattsson and Von

Schoultz (1974), both double-blind, did not find lithium to be more

effective than placebo in treating the PMS.

The women in Singer's

study (n=19) showed equal improvement under both conditions, but
12

of these women also suffered from other psychiatric conditions

throughout the remainder of the cycle which suggests that this sample
did not represent the PMS as it is commonly defined.

PMS group did meet the normal criteria:

Mattsson'

regularly recurring

symptoms which appear 7-8 days prior to the menses and are relieved
by the first or second day of the menses and do not occur at any

point during the remainder of the cycle.

This study did, however,

fail to differentiate between subgroups of PMS symptomatology,
fluid retention
i.e., anxiety-tension, depression, irritability, and
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(Steiner and Carroll, 1977).

Failure to make these distinctions

is common in the PMS literature.

More recently, researchers have

been advocating the importance of distinguishing among various
PMS symptom typologies, since it is possible that these subgroups

may be the result of different underlying causes (Halbreich, Endicott
and Schacht, 1982; Haskett

,

1981; Sampson and Prescott

,

Steiner, Osmun and Carroll, 1980; Osborn,
1981; Steiner and Carroll, 1977).

In

the Mattsson study, placebo was found to be the most effective

treatment, followed by a diuretic, with lithium the least effective
of the three treatments.

Steiner and Carroll (1977) conclude that

the effectiveness of lithium in treating various subtypes of the

PMS is still an open question.

It should be kept in mind, however,

that the same criticism (failure to distinguish among symptom

typologies) could be made of most PMS research to date.
The relationship between premenstrual changes and mental disorder

has been explored, but results have been inconsistent (Endicott,

Halbreich, Schacht and Nee, 1981; Halbreich, Endicott and
Schacht, 1982; Haskett, Steiner, Osmun and Carroll, 1980).

Again,

the direction of recent work is toward delineating between PMS

and premenstrual worsening of psychiatric disorders.

Authors who

have selected women with only PMS have concluded that PMS is not
diagnostic
typically a syndrome of anxiety or depression in the usual
for recurrent
sense and that it should not be thought of as a model

Carroll, 1980).
affective disorders (Haskett, Steiner, Osmun and

This

,
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finding suggests that lithium treatment may
not be useful in the PMS
since the rationale for the use of lithium
was originally based on
the resemblance of the PMS to cyclic affective
disorders.

Psychological-Personality Variables
The unusually strong placebo effect seen in most
premenstrual

research suggests that psychological and social factors may be
involved in the PMS (Gonzalez, 1981; Jordheim, 1972; Mattsson and von
Schoultz, 1974; Sampson, 1979; Watts, Dennerstein and De La Home,
1980)
.

The myriad of seemingly unrelated symptoms associated with the PMS
led many to hypothesize that the PMS was a psychosomatic disorder
as early as 1938.

Unresolved oedipal conflicts and/or marital conflicts

were postulated as the source of this disorder.

Women were thought

to be unconsciously expressing stress or poor attitudes toward

womanhood through their menstrual symptoms (Reid and Yen, 1981).
Authors have reported correlations between premenstrual changes and

disturbed attitudes toward menarche and the menses, guilt around
sexual feelings, severe medical and gynecological histories, poor

marital adjustment, and high neuroticism scores (Reid and Yen, 1981).
Although not of high quality, the psychoanalytic literature
shows a similar picture (Steiner and Carroll, 1977).

In one study,

questionnaires were sent to 103 women and it was concluded that, for
these women, menstrual problems were related to traumatic menarche

experiences

(

Shainess

,

1961).

Other analysts have postulated that

future
the mother-daughter relationship is important in determining

,
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attitudes toward menstruation and femininity in
general (Deutsch,
1944).
(1961)

Fortin, Wittkower and Kalz (1958), May
(1976), and Paulson
also associated rejection of the feminine role and
sexual

guilt with premenstrual symptoms.
today.

This view may still be prevalent

It would be interesting to conduct a survey of attitudes

toward the PMS among medical and psychiatric professionals.

Premenstrual symptoms have been correlated with various personality factors.

Coppen and Kessell (1963) found that neurotic

patients showed the highest premenstrual irritability.

Dinnerstein and

De La

Home

(1980)

Similarly,

Watts,

found that women with the PMS

scored higher on trait anxiety and neuroticism scales, as well as
had more negative attitudes toward their bodies, genitals, sex
and masturbation than controls.

In 1975

,

Smith, in his review of

this literature, concluded that the evidence suggested that tense,

anxious individuals, possibly having negative attitudes toward
their sex role, are more likely to complain of premenstrual irritability, even though nonneurotic women may suffer the same symptoms.
In the case of neurotic individuals, however, it is difficult to

determine which comes first, the cart or the horse, premenstrual
problems or neurotic tendencies.
Somewhat in contrast to Smith's conclusion, Blank, Goldstein
literature,
and Chatterjee (1980), in a more recent review of this
of
concluded that although some evidence suggests that severity

personality
prementstrual symptoms may in part reflect underlying
doubts on this
variables, the bulk of recent literature casts serious
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hypothesis.

In particular, these authors
cited recent dissertations

by Kleinsasser (1976), DiNardo
(1975), and Seagull (1974) which

attempted to correlate neuroticism,
sociability, self-sufficiency,

introversion-extroversion, dominance-submission,
self-confidence,
locus of control, body attitudes, adequacy
of functioning, and

adjustment with premenstrual symptoms.

All three authors found that

these measures do not fluctuate with the
menstrual cycle or with

severity of the PMS

.

Seagull (1974) concluded that mood and

behavior do fluctuate over the cycle, but that personality
factors
do not.

Only introversion-extroversion seemed to have any predictive

value, with introverted women tending to rest more, avoid social

contact and report lowered performance efficacy levels during the

menstrual phase of their cycle (Kleinsasser, 1976).

Sociological-Attitudinal Variables
Sociological studies have suggested that social expectations in

many cultures provide women with the opportunity to express stress and
malaise, to regress and to be absent from work around the time of

menstruation.

Smith (1975) reviewed the work of authors who suggest

that these social expectations produce a self-fulfilling prophecy

effect for many women.

Gough (1975) administered psychological

inventories to 201 young women.

He found that the women who reported

the greatest amount of menstrual distress were low on socialization

and high on femininity subscales of the California Personality Inventory.

The opposite trend was seen in women who reported the lowest

.
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amounts of menstrual distress.
stein and

Home

(1980)

As mentioned above, Watts, Denner-

found that women with PMS showed more negative

attitudes toward their bodies, genitals, sex and masturbation
than
controls.

Tarpin (1976) found similar relationships between nega-

tive sexual attitudes and premenstrual distress.

May (1976) speculated

that premenstrual tension may be associated with helplessness or

loss of self-control during menstruation in women who he found to be

more assertive, less traditional, and having fewer inhibitions.

He

further hypothesized that women who became depressed premenstrually

were expressing another kind of anxiety or the view that menstruation
is an unclean and shameful process.

May's hypothesis that helplessness

and loss of self-control may be associated with premenstrual tension
is contradicted by Seagull's (1974)

findings that measures of

self-sufficiency and locus of control do not vary over the menstrual
cycle

Based alone on the high placebo response rate seen in premenstrual
research, it seems fair to assume that personality and social-attitudi-

nal factors play a role in the development and expression of

premenstrual symptoms.

It is also likely, however, based on the

physiological literature, that somatic factors play as large, if not
larger, role in influencing the PMS (Parker, 1960; Reid and Yen,
1981; Smith,

1975; Steiner and Carroll, 1977).

It seems clear that

psychological and physiological interactions are inseparable and
circular in their ability to influence each other.

It is probably
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futile to attempt to rate either factor as more
or less important.
The most useful model seems to be one that
conceptualizes a

complex, and perhaps circular, pattern of interaction
and feedback

between psychological-social and physiological variables.

Performance
Feminists have long argued that fluctuations in the menstrual
cycle and concommitant fluctuations in hormonal levels ("raging

hormones") do not render women incompetent or unreliable in terms
of performance on the job or elsewhere.

In fact, this arguement is

well supported by the literature (Blank, Goldstein and Chatterjee,
1980)

.

An exception is some work of Dalton's, reviewed by Tasto and

Insel (1977), which suggests that lowered performance may occur
in adolescent women during menstruation.

She studied school girls

in an English boarding school and found that

f orgetf ulness

increased

menstrually in the girls who were more intelligent and free of
psychological stress.

She has also found lowered examination

performance in similar studies.

It is not clear how well conducted

these projects were.
Blank, Goldstein and Chatterjee (1980) have reviewed the perfor-

mance literature more extensively.

Mild decreases in performance

were found premenstrually and menstrually in a study by Stocker
(1974).

Contrary to these findings, is the work of Berstein (1977)

and interwho found no differences between premenstrual/menstrual

women.
menstrual academic performance in a sample of college

Both
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Golub (1974) and Summer (1972) found no differences in
intellectual
test scores over the menstrual cycle, although Golub's
subjects

made subjective reports and had expectations to the contrary.

(It

is interesting to speculate about the meaning of these
negative

expectations.)
findings.

Zimmerman and Parlee (1973) also support these

Basic sensory-motor processes

,

and concentration time showed no changes.

such as reaction time
This trend also seems

to be true for speech fluency (Silverman and Zimmer, 1976).

In spite of Dalton and Stocker's findings, the literature

fairly consistently challenges the social stereotype that women are
not as competent during the premenstrual and menstrual phases of
the cycle.

But for women who suffer from severe PMS

,

this may

not be the case.

Research Objectives

Although it seems logical that some form of dietary supplementation might ameliorate premenstrual symptoms (indeed, vitamin therapy
has dramatically increased in popularity among lay people in recent
years)

,

very little controlled research has been done to test the

effectiveness of nutritional supplementation in treating the PMS.
Renewed interest in vitamin B6 therapy occurred with the

discovery that this vitamin acts as a coenzyme in the biosynthesis
of the neurotransmitters dopamine and serotonin.

neurotransmitters have been implicated in
of mood and behavior (Reid and Yen,

1981).

a

Both of these

variety of disorders
Vitamin B6 is involved
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in many other metabolic activities, including
protein synthesis,

converting glycogen to glucose to provide energy for muscle
tissue,
the production of red blood cells, proper functioning of
nervous

tissue, and the metabolism of certain fatty acids (Robertson,

Flinders and Godfrey, 1976).

In view of the many decarboxylase

and transaminase reactions that are vitamin B6 dependent, it is

likely that a functional deficiency of pyridoxine would manifest
itself in several ways
(Winston, 1973).

clinically, and not only as depression

This potential for multiple manifestations is

attractive in relationship to the PMS, given the variety of symptoms
that can be associated with this syndrome.

Along with dopamine and serotonin synthesis, vitamin B6 has
been linked to improper glucose metabolism (Winston, 1973), estrogen

metabolism (Biskind and Biskind, 1943), prolactin levels (Mcintosh,
1976), and premenstrual depression in women on oral contraceptives

(Adams

e_t

al_.

,

1973)

.

Many normal American diets may be marginal in

vitamin B6 content, since 75% of this vitamin is removed by food
processing such as milling and heat (Robertson et

al_.

,

1976).

It has

recently been estimated that 2-18% of the population may be vitamin
B

deficient (NES, 1971-72).
the PMS
The possibility that pyridoxine may be useful in treating

still needs further substantiation (Reid and Yen, 1981).

Given the facts

of
mentioned above, it is likely that nutritional supplementation

symptoms
pyridoxine might have beneficial effects on premenstrual
and in particular, premenstrual depression.
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The present research effort was designed to examine the
effects
of vitamin B6 supplementation on the premenstrual
syndrome.

vitamin B6

,

If

in fact, has beneficial effects on physiological

functioning, these beneficial effects should eventually act to

decrease premenstrual dysphoria, and perhaps other symptoms as well.
One would expect to see a decrease in reported depression, irrita-

bility, tension, and anxiety during the premenstruum

.

This

research was specifically designed to assess the hypothesis that

vitamin B6 may exert beneficial effects over time on levels of

depression and anxiety.

Preliminary Research Findings
To examine the effectiveness of pyridoxine supplementation on

premenstrual symptoms, a pilot study was designed using a double-blind

crossover procedure.

Advertisements were placed in local newspapers

asking for volunteers.
ing selection criteria:

These women were screened based on the follow-

women could not be taking any oral contra-

ceptives, be on any regular medication or in poor health.

They

had to be between the ages of 20 and 40 and have fairly regular

menstrual cycles.

Volunteers were told that they would receive

a token sum if they completed at

least four months of the study and

of the study,
an additional sum if they completed the entire six months

these
Approximately 80 telephone responses were screened and 40 of

data collection.
callers were recruited for an initial interview and

record keeping, a
Of the 30 subjects who agreed to begin the home
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final sample of

9

subjects completed six months of a
parallel study

examining the effects of dietary sodium intake,
and only

4

subjects

completed six months of the pyridoxine pilot study.

Baseline data were collected over the first two
months of
the project.

During this time, a routine of home record keeping

and three monthly office visits was established.

Subjects were

asked to fill out 12 questionnaire packets per month.

These 12

packets were filled out starting on day one of the cycle, for the
first three days of menstruation.

The second group of packets was

filled out for three days during the follicular phase and prior to

ovulation.

(Interviewers carefully worked out individual schedules

with each woman according to the expected length of her cycle.)

The

third set of questionnaires was filled out for three days during the
luteal phase (about 10 days prior to menstruation)

,

and the final

set was filled out as nearly as possible to the last three days

before the onset of the next cycle.

The rationale for this approach

was based on the need to gather data from different phases of the
cycle, yet minimize the time and effort that would be demanded from

volunteers.

It was found, however,

that even for subjects who

reportedly had regular cycles, there was enough variation in their
cycle length to make it difficult to accurately calculate the phases,
so that in a number of instances women started their next cycle while

filling out the premenstrual packet, or conversely, ended up not

starting the next cycle for a considerable time following what was
to have been the premenstrual set of questionnaires.

This problem

,
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will be addressed in the research described here.

In addition to

home records, subjects were asked to come into the
research office
three times per cycle to deliver their completed
questionnaires and
to have their weight and blood pressure checked.

After baseline data were gathered for two complete cycles, the

experimental procedure was begun.

Each of the

4

subjects

was randomly assigned to take either the placebo or the vitamin B6

supplement,
150 mg/day.

times per day, one tablet with each meal, totalling

3

No other dietary changes or manipulations were made.

After a two month period the crossover was begun and the groups
were reversed.

Interviewers who met with subjects and supplied

them with the tablets were blind to the condition of the subject.
Home record keeping included the short form of the Zuckerman
and Lubin (1965) Multiple Affect Adjective Check List, which has

scales measuring levels of depression, anxiety and hostility.

It

also included the Moos Menstrual Distress Questionnaire (MDQ)

which has a number of scales reflecting

a

variety of affective,
In

behavioral, and physical menstrual cycle symptoms (Moos, 1968).
addition to these standard instruments, the packets included food

frequency check lists with

a

representative assortment of common

foods which were scored for rough indications of sodium intake, sugar

intake, and total intake, as well as B6

and potassium intake.

Finally

subjects to assess
the packet contained a brief questionnaire asking
stressors, and
their appetite, activity level, number of experienced

food cravings.
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Thirty-six subjects completed the baseline period of
two
months.

Average scores for the four phases of the cycle were

calculated using these subjects' data.

These averages revealed a

U-shaped pattern if plotted over the month.

Increasing levels of

negative affect were seen menstrually, followed by lower levels
during the mid-cycle phases (follicular and luteal), with a gradual
increase in negative affect occurring again during the premenstrual
phase of each cycle.

This U-shaped pattern was seen in all of the

measures of dysphoric mood.

As might be expected, arousal (positive

affect) showed the opposite pattern, increasing in the mid-cycle

phases and decreasing in the menstrual and premenstrual phases.
In order to examine the data for overall changes in moods

between the baseline, treatment and placebo phases of the study,
an average over all phases of the cycle was calculated.

When

these overall baseline, placebo, and treatment phase means were

calculated on the

4

subjects in the B6 study, all mood measures

except hostility and arousal were lowered under both the placebo
and the treatment conditions.

Both the Moos and the MAACL measures

of anxiety and depression showed this trend, and it was also seen
in the Moos measure of amount of mood swing.

The additional decline

associated with vitamin B6 supplementation, beyond that consistently
seen under the placebo condition, was usually small.

The largest

depression
increased effects of B6 were seen in the Moos measures of
closely behind.
and mood swing, although placebo effects followed
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Treatment with B6 was consistently more effective
than treatment with

placebo alone.

But these differences were small.

When similar comparisons were made looking at water
retention and

menstrual pain, treatment with vitamin B6 made
ment than placebo.

a greater improve-

As might be expected, declines during the menstrual

and the premenstrual phases of the cycle accounted for the largest

portion of the overall decline in the pain and water retention
measures.

Hostility and arousal (positive affects) do not seem to

have been affected by B6 supplementation.

With a sample size of 4, these results are very likely to reflect
chance variation.

But declines in levels of depression, anxiety,

mood swing, water retention, and menstrual pain suggested that
further research was needed to examine the possibility that B6

supplementation might be significantly more beneficial than treatment
with placebo in ameliorating the negative affect experienced

premenstrually and menstrually.

Discussion of Methodology
The pilot study was handicapped due to small sample size and

large amounts of variability in measurements, making it difficult to

detect what are perhaps subtle effects on mood levels resulting
from changes in dietary intake.

Variability was introduced by

inaccurate calculation of menstrual cycle phase, seasonal changes,
age
random life events affecting within subject variability,
a variety of
differences, and perhaps differential responses from

premenstrual subtypes.

to be
The most serious problem overall seemed
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the extreme variability of subject responses from cycle
to cycle.
As might be expected, moods and food intake are highly
responsive to

external stimuli as well as to menstrual cycle phases.
influences
students

—

—

Seasonal

including holidays, weather, and semester endings for

can mask more subtle cyclic effects.

Using more subjects

or investigating individual patterns more carefully by using a

longer time period are possible approaches to this problem.
The willingness of subjects to keep records was encouraging.
In follow-up interviews, subjects tended to object to the record

keeping the least, and to the office visits the most, suggesting
that future increases in the amount of home record keeping demands

would be feasible.

Matching subjects for age and symptom typology

would lessen between-subject variability.

Recruiting several

separate groups of volunteers, each overlapping one month in their

participation, would control for some variation due to seasonal
changes and academic schedules.

It was also found to be important not

to rely on retrospective reports on menstrual symptom severity, since

this pilor revealed an interesting discrepancy between retrospective

reports of symptoms and daily reports of symptoms.

Before formally introducing the methods adopted for this research,
researchers in this
it would be useful to summarize comments other
the considerafield have made regarding methodology in addition to

tions mentioned above.

Defining severity and subclassif ying premenstrual
changes
recently have become more important factors in
PMS research.
The etiology of the PMS still remains obscure and
the major reason
for this obscruity may be the wide variation in
definition found
in this field.

The importance of descriptive clarity, reliability

of measurement and classification has been highlighted
in recent

articles (Halbreich, Endicott

,

Schacht and Nee

,

1982; Steiner,

Haskett and Carroll, 1980).
Most researchers have used a single definition of premenstrual

syndrome that combines different dimensions of change or symptoms
that might be seen premenstrually (Halbreich

et^ al_.

,

1982)

.

Moos

(1969) has attempted to delineate dimensions of premenstrual change
to some extent by factor analyzing common symptomatology (47 items)

into

8

symptom clusters:

pain, water retention, concentration,

behavioral change, autonomic reactions, negative affect, arousal,
a control scale.

severity.

ar

These scales also allow for some assessment of

More recently, Steiner, Haskett and Carroll (1980) have

attempted to develop more specific criteria for the premenstrual
syndrome.

They have developed two scales for rating the severity

of premenstrual symptoms based on a study of women with severe

premenstrual symptoms and no evidnece of symptoms

at other phases

their menstrual cycle, and who had reported premenstrual dysphoria
for at least six consecutive cycles.

From this data and previous

criteria
research, these authors established a research diagnostic

oJ

.
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for a single premenstrual tension syndrome.

Based on the work of Moos and the authors
above,

a

new assess-

ment, the Premenstrual Assessment Form (PAF)
has been developed which

attempts to further delineate subtypes of mood,
behavior and physical
changes be defining inclusion and exclusion criteria
with cut-off
points to aid in differentiation (Halbreich, Endicott and
Schacht, 1982;

Halbreich, Endicott, Schacht and Nee, 1982).

The diagnostic criteria

developed by Steiner, Haskett and Carroll (1980) was used in this
research to verify that subjects did, in fact, suffer from the PMS
The PAF was used to further differentiate between symptom typologies

when possible.
Consistent with the findings of the pilot study are reports by
other researchers that retrospective ratings are frequently discrepant
from data obtained daily throughout the menstrual cycle.

It has

been suggested that the mood of a subject on the date which the

rating is undertaken may be responsible for this discrepancy
(May,

1976; Sampson and Prescott

,

1981).

Assessing premenstrual

symptoms at a predetermined time can be difficult, since the menstrual
cycle is generally somewhat unpredictable from month to month (Sampson
and Prescott, 1981).

pilot study.

This problem was of major significance in our

Also, if there is no record of a subject's scores during

non-premenstrual phases, there is no way to assess symptom patterns.
Daily or every-other-day recording of symptoms appears to be the most
reliable method of assessing symptom patterns and degree of severity
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(Rossi and Rossi,

1980; Sampson and Prescott

,

1981).

It is still

possible that social stereotypes might influence how
subjects rate
their moods and symptoms; however, with a controlled
experimental

design and large enough sample sizes, treatment effects
should
still appear if they exist.

Sampson and Prescott (1981) recommend self-ratings of moods and

physical symptoms over observed behavior or rater assessments.
In assessing treatment, observable behavioral events are normally

going to be too few in number to indicate response to therapy and
there is no agreement about whether measures such as the galvanic

skin response and reaction time are related to symptom severity.

Rater assessments are usually weakly correlated with self -ratings

when based on projective tests and interviews suffer from the same
drawbacks as retrospective ratings.

Among the self-rating methods which are available and commonly
used are individual checklists using a 3-4 point scale or

a

10 cm line scale, more general anxiety and depression scales (Beck

depression scale, Zuckerman and Lubin check list), or the Moos
Menstrual Distress Questionnaire (MDS)

,

which is specifically

designed to assess menstrual cycle symptomatology.

The MDQ appears

to be the most widely used self -rating scale in PMS research

(Sampson and Prescott, 1981).
treatment
Statistical problems can result in assessing whether a

placebo response, as
is better than a placebo when there is a high
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in the case of PMS

.

It is, therefore, necessary to have an
untreated

cycle before assessing treatment response and to
ensure that a

subject actually does fit the diagnostic criteria for PMS.

This

research project has been designed with these considerations
in mind.

CHAPTER

II

METHOD

Setting
This study was primarily conducted in the home environment.

Subjects were asked to keep daily records of their moods and menstrual
cycle symptoms.

These records were filled out by each subject in

the evening to insure, as much as possible, that similar conditions

prevailed when ratings of moods and other symptoms were recorded.
One monthly visit to the research office was required.

The

visits were scheduled according to individual cycles so that they

occurred during the mid-cycle phase.

Follow-up interviews with

participants from the pilot study indicated that subjects were most
reluctant to make office visits and least reluctant to keep home
records.

It was hypothesized that subjects would be more willing to

make office visits when they occurred during the mid-cycle phase,

rather than during perhaps more difficult menstrual and premenstrual

phases of the cycle.
3

to

1

The number of appointments were reduced from

/month, and record keeping was increased from a total of 12

days /month (divided into four 3-day segments) to daily record keeping.
months
Length of participation was reduced from six months to three
in duration.

The goal of these modifications was to maximize the numb

but intensifying
of participants by minimizing the time commitment,

record keeping demands.
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Subjects
Fifty-five women participated as subjects.

Subjects were recruited

on a voluntary basis and received $12.00 upon completion
of the study.

Advertisements were placed in local newspapers and university
bulletins.

Approximately 110 telephone responses were screened and

83 of these callers were recruited for an initial interview.

Initial in-person research office appointments were scheduled for

women who met the following criteria:

Absence of oral contraceptives

and an I.U.D.; lack of regular medications and any serious medical

problems; women had to be planning to stay in the area and not be

planning a pregnancy; women could not be taking more than

a common

daily vitamin supplement; and they must have reported regular recurring

premenstrual mood changes that were moderate to severe in nature and

noticeable to friends or relatives.
fairly regular menstrual cycle.

Women also had to have a

Women who reported that they occasion-

ally skipped cycles were not allowed to participate.

The mean age

of the participants was 28, and ages ranged between 17 and 41.

Initial interviews involved further description of symptoms
and their timing.

These interviews provided an in-depth description

were
of the study to volunteers and details about home record keeping

provided.

Women were then asked if they were willing to participate

for three monthly cycles.

These interviews were conducted by trained

undergraduate research assistants.
home record keeping,
Of the 74 subjects who agreed to begin the
three months of the study.
a final sample of 55 subjects completed

46

This tally represents a 26% dropout rate
and is a marked improvement
over the 57% dropout rate seen in our pilot
study.

This improvement

suggests that minimizing time commitment and
intensifying record

keeping did act to maximize the number of participants.
Research Design
A placebo controlled, double-blind procedure was used.

In order

to avoid crossover effects, as well as minimize time
commitment on

the part of volunteers, this project did not use a crossover design

balanced for crossover effects as was used in the pilot study.
it was

hypothesized that seasonal influences

and semester endings for students

—

—

holidays, weather,

might mask more subtle cycle

effects on mood, three separate groups of subjects were run (Gi

GUI), each

Because

,

Gil,

for a three-month period, at three times of the year, such

that each group overlapped in duration with the previous group in an

attempt to balance for seasonal effects.

Figure

1

illustrates when each

group of subjects began in the study, the range of duration of their

participation, and where they overlapped in time.

Holidays and exams,

which are thought to be particularly stressful times of the year,
are noted in the figure.

All subjects were asked to describe their menstrual cycle symptoms
in detail and were asked to describe an average day's food intake.

All women were asked to keep baseline home records for

a

period

next
of one menstrual cycle, beginning on day number one of their

cycle.

Volunteers were then asked to take a vitamin B6 supplement or

meal, totalling 150 mg/day
a placebo three times per day, or once with each
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FIGURE

1.

Range of duration and overlap of Groups I, II,
and III across seasons with holiday, exam, and
tylenol scare periods highlighted. In Group I,
50% of the subjects were in the third month of
the study during the stressful winter exam and
holiday season. In Group II, 59% of the subjects were in the first month, or baseline
phase of the study during the holiday season.

.

.

.
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for those on the vitamin B6 supplement.
a

Subjects in Group

I

received

matching small white tablet form of placebo and
vitamin B6

Subjects in Group II and Group III received placebo
and vitamin B6 in

matching brown gelatin capsules.
planned.

This aspect of the study was not

The serendipity of this procedure led to seeing
differential

placebo effects, as will be discussed in the results section.
Subjects were blind to the treatment, as were their interviewers.
In order to assure uniformity of groups, subjects were matched for
age

and premenstrual symptomatology as closely as possible and then randomly

assigned to receive either the vitamin or placebo.

balanced across subjects for age and condition.

Interviewers were

No significant differ-

ences in baseline scores were seen between any of the three groups (Table
and demographic characteristics matched as well (see Table

2

)

Volunteers continued their home record keeping for two cycles while on
the placebo or vitamin supplement.

At the end of the entire three

month period, subjects were told which condition they were under,
received payment, and a full description of the study, including a

description of their own menstrual cycle variations in mood and other
symptoms

Procedures and Measures
The constructs of interest in this study were mood and physical
symptoms.

A pretest measure of general menstrual cycle symptoms was

given to each subject at the intial interview in order to differentiate
and
between those who fit diagostic criteria for PMS (Steiner, Haskett

1)
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Table

1

Summary of Paired t-Test Comparisons
on Baseline
Levels between Groups I, II,
and
III

(none significant)

.Group

Anxiety-Semantic Differential

I

Group II

(«*

= .005):

Group III

F-ratio

d.f

Cycle Average

f!"
S D
-

-

Premenstrual Phase
Ave
-

S

2

«

-

D

-

5

185

5

-^9

53

0.879

4.983
1.426

0.840

1.361

6.118
1.730

6.052
0.994

5.726
2.352

0.255

53

'

Depression-Semantic Differential (*=.005):
Cycle Average
Ave
-

S-D.

4.880
1.233

5.285
0.780

4.803
1.221

1.150

53

5.655
1.582

5.639
1.030

5.610
1.966

0.004

53

Premenstrual Phase
Ave.
S.D.
3.

All Negative Affect-Semantic Differential (<*=.005):

Cycle Average
Ave.
S.D.

5.097
1.240

5.545
0.761

5.111
1.306

1.080

53

5.941
1.600

6.020
0.914

5.816
2.053

0.083

53

Premenstrual Phase
Ave.
S.D.
4.

Perceived Stress Level-Semantic Differential (^=.005):
Cycle Average
Ave.
S.D.

5.114
1.345

4.884
1.018

4.659
1.082

0.666

53

5.249
1.842

4.540
1.469

4.997
2.010

0.841

53

Premenstrual Phase
Ave.
S.D.

.
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Table

1

(continued)

Group
5.

Cycle Average
Ave.
S

'

D

-

Premenstrual Phase
Ave
-

S

6.

-

D

-

Group II

Group III

F-ratio

d.f.

2.245
0.477

2.108
0.391

2.123
0.680

0.397

53

2.278
0.647

2.409
0.701

2.510
0.844

0.438

53

Poor Concent rat ion-MDQ-T (<*=.005):
Cycle Average
Ave
-

S.D.

Premenstrual Phase
Ave
-

S.D.
7.

I

Menstrual Pain-MDQ-T (* =.005)

1.747
0.467

1.650
0.461

1.576
.0552

0.521

53

1.963
0.731

1.841
0.585

1.906
0.880

0.141

53

1.717
0.501

1.571
0.320

1.513
0.552

0.929

53

1.796
0.658

1.682
0.547

1.677
0.776

0.194

53

Behavior Changes-MDQ-T (c*=.0Q5):
Cycle Average
Ave.
S.D.

Premenstrual Phase
Ave.
S.D.
8.

Autonomic Symptoms-MDQ-T
Cycle Average
Ave.
S.D.

(<* =

.005):

1.320
0.394

1.344
0.374

1.374
0.445

0.078

53

1.500
0.454

1.545
0.722

1.531
0.591

0.028

53

Premenstrual Phase
Ave
S.D.
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Table

1

(continued)

Group
9.

Water Retention-MDQ-T
Cycle Phase
Ave
-

S

-

D

-

Premenstrual Phase
Ave
-

S

10.

-

D

-

(£*'=.

I

Group II

Group III

F-ratio

d.f

005)

2.187
0.368

2.237
0.476

2.218
0.747

0.042

53

3.056
0.802

3.318
1.041

3.177
0.995

0.376

53

2.354
0.693

2.328
0.594

2.225
0.662

0.189

53

2.583
0.845

2.591
0.766

2.604
0.935

0.003

53

2.501
0.653

2.349
0.650

1.978
0.699

2.752

53

2.343
0.942

2.227
0.703

1.719
0.632

3.137

53

1.297
0.495

1.183
0.267

1.189
0.240

0.615

53

1.380
0.832

1.250
0.370

1.313
0.544

0.231

53

Negative Af f ect-MDQ-T (c*=.005):
Cycle Phase
Ave
-

S-D.

Premenstrual Phase
Ave.
S.D.
11.

Positive Af f ect-MDQ-T («*=.005):
Cycle Phase
Ave.
S.D.

Premenstrual Phase
Ave.
S.D.
12.

Lack of Control-MDQ-T (#=.005):
Cycle Phase
Ave.
S.D.

Premenstrual Phase
Ave.
S.D.
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Carroll, 1980) and to further
differentiate between premenstrual

symptom typology (see Appendix

A)

Initial assessment included the
Premenstrual Assessment Form (PAF)
developed by Halbreich et al (1981).
The PAF asks a woman to rate her
.

last three cycles overall, to rage only
the premenstrual phase of those

cycles, and to rate the degree of symptom
change from normal levels.

The PAF contains 94 items which enable it to
make fine distinctions

between symptoms.

This form was used for initial assessment,
subtyping

and for matching subjects in this study.
An initial interview designed for the purposes of
this study was

also administered.

This interview was conducted by research assistants

and asked that each woman describe a typical day's food intake, the
onset, duration, severity and type of menstrual symptoms they regularly

experienced.

They were asked if these symptoms peaked at any point,

and when symptoms ended (see Appendix A)

During the three months of the study, each woman rated her mood
on a daily basis and her menstrual symptoms every other day.

The Moos

Menstrual Distress Questionnaire, form T (Moos, 1969) was used to
measure change in menstrual symptoms.

menstrual symptoms she experiences on

It allows a women to describe th
a daily basis.

A list of 47

symptoms commonly experienced menstrually and premenstrually are each
rated in severity on a 1-6 scale.

This scale provides a measure of

absoluate degree of symptoms in contrast to the PAF, which attempts
to measure degree of symptom change from normal baseline levels.

The

MDQ-T items have been factor analyzed and fall into eight symptom
subgroups:

pain, water retention, concentration, behavior change,

negative affect, arousal (positive affect), autonomic reactions, and

.

,
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control.

The symptom subgroups of major
interest in this study were

negative affect, arousal, pain, and water
retention.

The pain scale

reflects symptoms usually associated with
dysmenorrhea, whereas the

negative affect scale reflects symptoms
generally associated with the
PMS (see Appendix A)

A semantic differential form designed to rate
levels of anxiety,

depression and stress was administered daily to each
woman.

This

checklist contains ten items selected to reflect depressive
moods,
five items to reflect anxiety, and one item which rated how
stressful
the day was perceived to have been.

Adjectives which are polar oppo-

sites of each other were separated by a 10cm line (Osgood, Suci

Tannenbaum, 1957)

.

Women were asked to indicate how they felt on that

day by marking along the line in the place that best described their mood
for the day.

Adjectives reflecting depressive mood were selected from

the Zung Self-Rating Depression Scale (Zung, 1965) and the Radloff

Depression Scale (Radloff, 1977).

Items reflecting anxiety were

selected from the State-Trait Anxiety Inventory (STAI, Form XI)
designed by Speilberger, Gorsuch and Lushane (1968).

To avoid a halo

affect in the daily mood measure, five separate alternating forms were
used, each containing the same items, but counterbalanced and scrambled
in order.

Subjects were told that each form was not identical to the other

and that care should be taken in filling them out. (see Appendix A).

Women were asked to return all unused pills at the end of each
month's cycle, so that compliance could be assesses by pill counts.
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Postcards were mailed to remind
subjects to return forms by
mail on
bi-weekly basis, and telephone reminders
were made before each

scheduled office appointment.

a

Exact rate of compliance could
not be

obtained, since pill counts were not
completed on every subject.

Estimates of compliance were based on
completed pill counts only.
These estimates are fairly consistent
across groups (Group

I

= 86.8%;

Group II = 87.5%; and Group III = 74.5%) with
Group III appearing to
be the least compliant.

Women were asked to fill out a post-study
questionnaire and received
a follow-up letter (see Appendix B)

.

CHAPTER III
RESULTS

Many authors assess the significance
of changes in systems by

subdividing the menstrual cycle into
phases and adding symptom scores
for each phase together.

Comparisons are then made between
scores

(Sampson and Prescott, 1981).

Phase definition, however, differs
often

from study to study, varying in number from
four to seven.

Rossi and

Rossi (1980), after an extensive review of the
literature and an analysis
of their own preliminary data, chose to divide
a cycle into five phases.

They assumed a 28-day cycle and made appropriate adjustments
for data
analysis when cycles exceeded or did not reach this standard length.
The criteria for phase definition, as outlined by Rossi and Rossi,

includes every day of the menstrual cycle, and separates these days
into a menstrual, follicular, ovulatory, luteal, and premenstrual

phases.

These divisions resulted from their findings that mood patterns

unique to the luteal phase existed and that premenstrual and menstrual
phase mood profiles were less consistent than expected.

Their protocol

for phase definition was used to analyze data generated from this study.

Group Equivalence
In order to assess whether there were any significant differences

between Groups I, II, and III at baseline, paired t-test comparisons
were made on each construct of interest.
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These constructs included a
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semantic differential measure of
Anxiety, Depression, overall
Negative
Affect, and Perceived Stress, as well
as MDO-T measures of Menstrual
Pain,
Poor Concentration, Behavior Change,
Autonomic Symptoms, Water Retention,

Negative Affect, Positive Affect, and
Perceived Lack of Control.

significant

No

differences in these measures were found
at baseline

between Groups I, II, and III (£ee Table
1).

Comparison of demo-

graphic variables between groups did not show marked
differences (see

Table

2

)

,

nor were there marked differences in compliance
rates

between groups as noted in the Method section.
that Groups

I

,

II

,

These data indicate

and III were equivalent in composition, compliance,

and in degree and duration of premenstrual symptoms.

Effect of Vitamin B6
In order to assess the effectiveness of vitamin B6 on ameliorating

premenstrual symptoms, an analysis was conducted on each individual
group.

In Group I, there was a significant effect of vitamin B6 on Poor

Concentration during the premenstrual phase of cycle three (F=19.90;
p < .005)

.

In Group I, effects which approached significance were seen

premenstrually in cycle number three in Negative Affect (F=14.40;
p < .01)

,

Behavior Change (F=13.40;

(F=11.27; p <.01).

p < .01)

,

and Autonomic Symptoms

In Group II, there was a significant effect of

B6 on Poor Concentration during the follicular phase of cycle number

two (F=41.65; p < .001).

A covariance analysis adjusting for baseline

values was conducted using a significance level of p< .005 (F^ ,8=14.69)
in order to control for variations that might exist across groups in

.
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baseline levels of menstrual symptoms.
and III were combined (n=56)

When data from Groups I, II,

there were no significant effects

,

revealed by the analysis of covariance
Three significant results (p

signifiance (p
12

< .01)

measures).

< .005)

and three results nearing

were obtained out of 72 tests

(2

At the p < .01 level, one would expect

cycles x
.7

3

groups x

significant

results by chance and .35 significant results by chance
at the

p < .005

level; therefore, it is unlikely that the six results
mentioned above

were obtained by chance.

Four of the six results were seen in the

premenstrual phase of cycle number three in Group

I.

In three of

these four cases, the vitamin B6 condition remained constant in measures

across time.

In all four cases, the placebo condition scores increased

(or worsened)

in value over time.

It is also interesting to note that

in three out of the six findings, the measure which was affected was

Poor Concentration as measured by the MOOS menstrual distress

questionnaire.

The size of the effects in Group

I

were relatively large.

Based on a six-point scale, the mean level of Behavior Change noted in
Group

I

during the premenstrual phase of cycle three was 2.7 in the
Similar size differences were

placebo versus 1.4 in the B6 condition.
seen for Autonomic Symptoms

Affect (X
(X

placebo

,

,

placebo

(

1,8 versus

X^

=

1-1); Negative

do

=

and Figure

2

3

=

placebo

3.3 versus X„, = 2.4); and Poor Concentration

=2.7 versus X^
Bo

ized in Table

x

1.5)

.

in Group I.

Figure

2

These findings are summar-

suggests that vitamin B6 was

more effective in improving Poor Concentration, Autonomic Symptoms, Water
Retention, Perceived Stress Levels, Behavior Change, and in increasing
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Paired t-tests which were significant or approached
significance in Group I. This figure illustrates
that the effect of vitamin B6 in Group I was to
hold premenstrual symptoms at an even level while
symptoms worsened under the placebo condition. It
also illustrates that this effect occurred in the
third month.
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Positive Affect than the placebo in Group
are compared.

I

when Mean Change Scores

Mean Change Scores baseline -(Mo

2

+ Mo

3) /2

J

illustrate the direction and size of change in
scores between the baseline and treatment phases of the study.

and size

of.

A pattern for direction

change in symptoms can be discerned from

inspection of Mean Change Scores.

a

visual

Again, in this case, Mean Change Scores

show that B6 was more effective than placebo as a treatment
in Group
Figure

2

I.

illustrates that the effect of B6 on Poor Concentration during

the premenstrual phase of cycle three in Group

I

is the result of placebo

scores having increased dramatically, while B6 scores remained fairly
constant during the third cycle.

This trend suggests that B6 perhaps

played a "protective role" by preventing a rise in Poor Concentration

which otherwise might have occurred.

Cycle three of Group

I

corresponded

with a potentially stressful time of the year for both female students and
employed women, winter finals and holiday season (see Figure 1).

In

Group I, 50% of the subjects were in cycle three of the study during winter
exams and holiday season.

Subjects reported a higher Perceived Stress

Level during this period when scores were compared to theoretically
less stressful periods of time.

In Group I, the mean Perceived Stress

Level score for the period between 12/15/82-12/26/82 was 5.47 as compared
to 4.89 for the period between 11/30-12/15 (an 0.6 point difference on a

1-10 point scale).

In Group II, the mean Perceived Stress Level score

for the period between 12/15-12/26 was 5.35 as compared to 4.5 for
on a 1-10
the period between 1/15/83-1/26/83 (an 0.85 point difference

point scale)

.

These averages are consistent with the suggestion that
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FIGURE

3.

*Mean change scores between baseline and treatment phase
conditions
of the B6 condition in Group I and placebo
This figure
Phase)
(Premenstrual
of Groups II and III
III had
and
II
Groups
in
illustrates that the placebo
vitamin
than
symptoms
premenstrual
a larger effect on
subjects.
B6 had on premenstrual symptoms in Group I
.

X

=

change

Baseline - £( Month

2

+ Month

3)

f 2

J

indicates improvement
*A change in the negative direction
in all measures
symptoms
in intensity of premenstrual
except positive affect.
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subjects in both Groups

I

and II perceived themselves to be
under more

stress during the winter exam and holiday
season than other periods
of the year.

Effect of Placebo

Paired t-test comparisons were made to determine
whether there were

significant differences between Group
of the placebo.

II and III in the effectiveness

I,

This was an important question, particularly because
the

perceptual characteristics of the placebo (and vitamin) varied
between
Groups

I,

and Groups II and III.

min in matching tablet form.

Group

I

received the placebo and vita-

Groups II and III received placebo and

vitamin in matching capsule form.

Paired t-tests revealed no signifi-

cant differences in the effect of placebo among Groups I, II and III.

Nevertheless, the placebo effect in Groups II and III is greater than
the effect of vitamin B6 in Group

I

premenstrual symptoms in 10 out of

12

compared (p

=

.00013;

of 12 measures*)

.

on lessening the intensity of

measures when Mean Change Scores are

for the chance of Group

Mean Change scores in Figure

scoring worst on 10 out

I

suggest that the

3

placebo in Groups II and III was more effective in improving Anxiety,
Depression, Negative Affect, Perceived Stress Levels, Water Retention,
and Positive Affect than vitamin B6 in Group

This trend is consistent

I.

with the hypothesis that differential placebo effects occurred in this
study.

The capsule form of placebo delivery used in Groups II and

III achieved a greater effect than the tablet form of vitamin B6

*Chance of 10 + chance of

11

+ chance of

12 = 55
12

+12_
„12

+

J_
12
3

=

.00013)

administration in Group

I.

It is also consistent with the
hypothes

that vitamin B6 is less effective in ameliorating
premenstrual

symptoms than placebo in capsule form.

CHAPTER

IV

DISCUSSION

In this dissertation, several goals were
addressed:

(1)

to

determine whether dietary supplements of vitamin B6 can
exert a

beneficial effect on premenstrual symptoms;

(2)

to develop a general

methodology suitable for studying the menstrual cycle;

(3)

to begin

the delineation of particular variables that warrant further

research; and (4) to develop a vigorously controlled method for testing

alternative treatments for premenstrual symptoms.

A significant amount

of progress has been made toward each of these goals.

Data from this study indicate that vitamin B6 may improve premenstrual symptoms under specific conditions which will be discussed
The hypothesis that vitamin B6 may exert beneficial effects

below.

over time on physiological functioning and premenstrual dysphoria was
not supported by combined analyses of data from all three groups

studied.

Nevertheless, a significant effect of vitamin B6 on improving

Poor Concentration was seen premenstrually in Group I.

Group

I

Also seen in

were beneficial effects during the premenstrual phase of

vitamin B6 approaching significance on measures of Behavior Change,
Autonomic Symptoms, and Negative Affect.

Similar effects on premen-

strual symptoms were not replicated in Groups II and III; however,
was seen
in Group II a significant effect of B6 on Poor Concentration

during the luteal phase of cycle number two.
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In Group III, a significant

69

effect of B6 was seen during the
follicular phase of cycle number
two
on Poor Concentration.

Differences in the premenstrual phase
findings

between Groups I, II and III cannot be
explained by variations in
compliance, demographics, or baseline measurement
levels.

Differential placebo effects could account for
Group
from Groups II and III.

I

differing

Perceptual characteristics of a placebo can

lead to differential levels of effectiveness, as
well as differential

duration of placebo effectiveness.

It is known that perceptual

characteristics of drug preparation can lead to changes in expectancies
regarding the efficacy of medications (Bukalew and Ross, 1981).

Both

color and size of preparation can affect the expected drug action and,
therefore, its efficacy (Bukalew and Ross, 1981; Bukalew and Cof field,
1982a; Jacobs and Mordan, 1979).

Capsule preparations were seen as

more powerful than a tablet, and white tablets, which resemble the
common aspirin (like that used in Group

I)

,

are perceived as less

powerful than other colored tablets or capsules (Bukalew and Cof field,
1982a)

.

This finding is more pronounced among whites than among

blacks (Bukalew and Cof field, 1982b).

The magnitude (and duration)

of placebo affect may have been increased in Groups II and III, both

Data

of which received capsules rather than tablets, as in Group I.

from Mean Change score comparisons support the hypothesis that there
was a larger placebo effect in Groups II and III (see Figure

4)

,

and

in addition, that this effect was greater than the effect of vitamin B6
in Group

1

(see Figure 3).

It

is possible that a true effect of B6
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FIGURE 4.

*Mean change scores between baseline and treatment
phases of the placebo condition.
(Premenstrual
phase comparisons only)
This figure illustrates
that in 10 cases out of 12, the placebo effect in
Groups II and III was greater in reducing symptoms
than that in Group I.
.

*A change in the negative direction indicates
improvement in intensity of premenstrual symptoms
in all measures, except positive affect.
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existed in all three groups, but was apparent
only in Group
strually (see Figure

5)

I

premen-

when compared to a relatively less effective

placebo due to its tablet form of preparation.

A small true effect

of B6 in Groups II and III could have been overshadowed
by a larger

magnitude placebo effect resulting from the use of capsules.

Whatever

the case, data from this study indicate that a placebo in
capsule

form is more effective than vitamin B6 in white tablet form.

This

finding does not, however, rule out the possibility that physiological

variables play

a role in the

etiology of premenstrual symptoms.

The

high placebo response rate in premenstrual research (Day, 1979;
Sampson, 1976; Steiner and Carroll, 1977) suggests that social-attitudi-

nal factors may play an important role in the development and expression
of premenstrual symptoms.

It is also possible, however, based on the

physiological literature, that somatic factors play an equally large
role in influencing PMS

.

The most useful model for the study of PMS

is one that conceptualizes a complex, and perhaps circular, pattern

of interaction and feedback between psychological-social and physio-

logical variables, as it is likely that psychological and somatic
factors are inseparable and circular in their ability to influence one
another.

To this author's knowledge, there has been no systematic

attempt to examime the true course and potential attenuation of

placebo responses compared to active treatment (Rubinov;
1984).

and Roy-Byrne,

comparaFurther research is warranted in order to assess the

premenstrual
tive usefulness of vitamin B6 over placebo in treating
effective than vitamin
symptoms, as a placebo in capsule form was more
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FIGURE

5

.

*Mean change scores compared between placebo and
B6 conditions in Group I.
(Premenstrual phase
comparisons only.) This figure illustrates that
in Group I, vitamin B6 was more effective than
placebo in decreasing premenstrual symptoms
in 6 out of 12 variables.

*A change in the negative direction indicates an
improvement in intensity of premenstrual symptoms
in all measures, except positive affect.
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B6 in tablet form in this study.

The discrepancies between premenstrual
phase findings in Group
I

and Groups II and III might also be the
result of stressful

seasonal events/holidays/final exams.

Seasonal effects could

account for. cycle three differing from cycles one and
two in Group

I.

As discussed in the Results section, in Group I, cycle
three, an

increase in Negative Affect, Poor Concentration, Behavior Change,
and

Autonomic Symptons were seen premenstrually in the placebo condition,
but not in the vitamin B6 condition (see Figure 2).

It is only

during the third cycle that B6 is more effective than placebo.

Since,

for most subjects in Group I, the third cycle coincided with either

academic finals or Christmas/holiday events (see Figure

1)

,

it is

possible that vitamin B6 may have acted in a protective fashion during
stressful periods by preventing an increase in premenstrual dysphoria

which otherwise would have occurred.
indicate that subjects in Group

I

Indeed, data from this study

were experiencing greater levels of

stress during the third cycle (see Results section)

may have differed from Group

with stressful time periods.

I

.

Groups II and III

because treatment phases did not coincide
If vitamin B6 is only effective in a

"protective" fashion during times of increases stress, effectiveness
of vitamin B6 supplementation would not appear during less stressful

time periods such as those during which Groups II and III were run,

thus accounting for the discrepancies between Groups II and III and

Group

I

in this study.

,

7b

It is thought that greater amounts of vitamin
B6 may be utilized

by the body during stressful periods and it is a
common recommendation

among lay people to use vitamin B complex supplements during
times of
stress.

However, to this author's knowledge, there have been no

studies directly assessing the effects of environmental/psychological

stressors on vitamin B6 status.

It is known that psychological stress

can result in faster transit times through the stomach and small

intestine in humans (Cann, Read, Cammack

,

Childs, Holden, Kashman

Longmore, Nix, Simms, Swallow and Weller, 1983).

Increased transit

times might result in decreased absorption of nutrients.

The require-

ment for B vitamins might be increased when metabolism is speeded up,
as in muscular exercise, exposure to cold (Bourne, 1948-49), or

possibly in response to environmental stressors.

Gyorgy (1938)

suggested that susceptibility to chilblains may be a function of

pyridoxine reserves in the body, and that supplementation with vitamin
Changes in the status

B6 could aid in the prevention of chilblains.

of other nutrients in response to stress have been documented.

Stress

is thought to alter the ratio of carnitines (a natural constituent
of animal tissue involved in lipid metabolism)

,

and it has been

postulated that exogenous carnitines may provide protection against
heart damage during periods of stress (Fanelli and Tenuta, 1981).

Vitamin B6 status may eventually be linked to increased susceptibility
to dysphoria during times of stress.

Indeed, data from this study

suggest that vitamin B6 may ameliorate premenstrual symptoms,

specifically during times of stress.

77

A separate, but equally interesting finding in this study, was
that vitamin B6 improved Poor Concentration levels in all three groups
of subjects studied.

Interestingly, these changes occurred in

different menstrual cycle phases across groups.
B6 improved concentration levels premenstrually

In Group I, vitamin
;

in Group II, concen-

tration was improved in the luteal phase; and in Group III, it was
improved in the follicular phase of the cycle by vitamin B6 supplementation.

It may be that concentration levels are more responsive to

vitamin B6 supplementation than mood or other physiological parameters.
Data from this study are consistent with the hypothesis that vitamin B6

may improve concentration levels regardless of menstrual cycle phase.
In summary, results from this study suggest that the beneficial

effects of vitamin B6 on menstrual symptoms include:

1)

a general

overall ability to improve concentration levels regardless of menstrual
cycle phase, and 2) an ability to improve some premenstrual symptoms

(including dysphoria) during periods of increased stress.

Ironically,

data from this study also suggest that a placebo in capsule form can
be more effective than vitamin B6 in tablet form in ameliorating

premenstrual symptoms.
Progress was made toward the development of

a general

methodology

testing alternative
suitable for studying the menstrual cycle and for
controlled manner.
treatments for premenstrual symptoms in a vigorously

Most research on PMS

,

including the pilot version of this dissertation,

by inaccurate calculation of
has suffered from variability introduced

random life events affecting
menstrual cycle phase, seasonal changes,

,

78

within subject variability, age differences, and
perhaps differential
responses from a variety of premenstrual symptom
subtypes.

This

study effectively avoided miscalculation of menstrual
phases due

tc
:o

irregularities in cycle length by shifting periodic record keeping
to daily sampling through record keeping.

The study also insured

that miscalculations did not interfere with proper timing of vitj:amm

intake by providing daily supplements to subjects throughout the

entire treatment phase.

The effects of seasonal weather changes

were controlled by running separate groups of subjects which overlapped
one month in participation over the academic year.

Variation within

subjects which can be introduced by random life events was addressed

through increasing the number of subjects who were able to participate, by decreasing the length of time required for participation,
and reducing office visits to a minimum (one visit /month)

.

Subjects

were matched for age and type of symptom using a diagnostic criteria

developed by Steiner, Haskett and Carroll

(

1980)

.

Indeed, these changes

in methodology increased the number of women who participated in the

study (the sample sizes in each group of this study were larger than

others reported in the literature examining the effects of vitamin B6)

avoided entirely the possibility of miscalculating menstrual cycle
phases, and theoretically should have reduced any variability that

might result from differential responses from various premenstrual

symptom subtypes.

7 9

The process of delineating particular
variables that warrant further

research was begun.

Serendipitously

,

the procedures used in this study

highlighted the importance of avoiding differential
placebo effects
and controlling for the effects of emotionally
stressful times of the

year as other factors which can introduce unwanted
variability.
in future research designs are indicated.

Changes

Differential placebo

effects could easily be avoided by matching placebo
preparation form
across conditions and groups.

Use of a less effective form of placebo

(tablet) would be recommended in order to determine whether vitamin B6

supplements have any effect, regardless of the strength of that
effect and its clinical significance.

The use of tablets would avoid

the possibility that subtle effects of vitamin B6 might be overshadowed
by larger placebo effects.

Use of maximum strength form of placebo

(capsule) would be recommended in order to determine the clinical

significance of vitamin B6 treatment, or whether a placebo can be
equally or more effective than vitamin B6

.

It would also be important

to run a parallel control group which received placebo and vitamin B6.

Seasonal effects, or the effects of emotionally stressful time

periods could be controlled by the use of a third No Treatment control
group, and through the use of more comparable subjects, i.e., only

students or only employed women.

Replicating the study with systematic

timing of data collection would allow for comparisons to be made

between stressful periods and non-stressful time periods or seasons.
It would be important to include more careful and direct measures of

.
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stress levels.

entire year.

Ideally, subjects should be followed
throughout the

Data collected during January, February
and March, as

well as during June, July and August, would
represent less stressful
periods (avoiding exams and holidays).

Data gathered during June,

July and August would also avoid the potentially
stressful winter

months.

If an effect of season were found, further research
comparing

the effectiveness of tablet versus capsule form of placebo
and vitamin
B6 would be needed.
In general, it would be important to increase the length of baseline

measurements only if it were necessary to address variability between
cycles in symptoms, since a longer study would reduce the number of

subjects who would continue to completion, thus reducing the representativeness of any data gathered as it becomes more biased through
self -selection

,

i.e., only representing those subjects who are willing

to participate for longer periods of time.

This dissertation has determined that vitamin B6 may have

a

beneficial effect on premenstrual symptoms during stressful periods of
time, and that vitamin B6 may improve concentration levels throughout
the menstrual cycle.

It has also determined that a capsule form of

placebo may be more effective than vitamin B6 in tablet form in

treating premenstrual symptoms.

Several improvements in methodology

introduced in this study have resulted in the ability to sample a larger

number of subjects and to minimize the introduction of unwanted
variability.

A more rigorously controlled method for testing altern-

and
ative treatments for premenstrual symptoms has been developed,

particular variables that warrant further research have been
delineated

.
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TELEPHONE SCREENING FORMAT

Interviewer

Caller

Call Number

Caller's Age

Date

Address

Where did she hear about this study?
Phone

NECESSARY POINTS TO MAKE

:

1.

The study will last
keeping at home

2.

Moods and menstrual symptoms will be monitored over those
months

3.

It will involve coming to Tobin Hall once a month to turn in the
previous month's home records and receive additional home record
forms

4.

They will be asked, after the first month, to take a dietary
supplement 3 times/day, with each mean, that will contain either
a supplement (such as a vitamin or mineral, not a drug) or a
placebo.

3

months and will involve daily record

****Does she feel her premenstrual mood changes are moderate to
severe in nature????

INFORMATION TO COLLECT

:

Must be between 25 and 40 (enter above also).

1.

Age

2.

Is she on oral contraceptives?

3.

Does she cycle regularly?

4.

Any serious health problems, or regular medication that she
takes?

5a.

supplement
Is she taking more than a multiple vitamin/mineral

regularly?
5b. Does she take Motrin or Ponstel?

Willing to go off it?

6.

to leave the area?
Is she planning a pregnancy or planning

7.

mood changes?
Do Friends or relatives notice her PM

(except cycling regularly)
****IF SHE ANSWERS NO TO ALL OF THE ABOVE
THEN PROCEED

,

:

SCHEDULE AN INITIAL INTERVIEW
1.

2.
3.

When is she expecting her next period to begin?
Schedule an appointment for her BEFORE it should

begin.

Inform her that this appointment does not commit her
or us
but that we will explain the study more fully and
get more'
information from her at this time. She will be asked to
fill out some questionnaires and will be given home
records
if she decides to participate.

Ask her for questions

—

repeat appointment time and sign-off****

.

INFORMED CONSENT FORM

understand that in this study I will be asked
to keep a regular
m menStrUal SyTnptoms and mood changes, and
that I will come
Ku
Ti once a month
to ?
Tobxn
Hall
to have my home record keeping checked
and
to receive additional record keeping forms.
I understand that after
a one month baseline period, I will be
asked to take three capsules
daily which may contain either a dietary supplement
or a placebo
(inert substance), which may or may not affect
my menstrual cycle
symptoms.
I understand that all of my records
and all other
experimental data will be kept completely confidential and
anonymous.
I

T

C r

I understand that the dietary supplement and
placebo represent no
risk to my health.
I also understand that if I participate for
3
months, I will receive $10 to $25 for my participation. I have been
informed that I may withdraw my consent and withdraw from the study
at any time without penalty.
I understand that although during the
study I will not be told what the dietary supplement is or whether
I will be taking a supplement or a placebo, at the conclusion of the
study I will be given all of this information as well as any other
information I wish to have about the methods and hypotheses of the study

Signature
Date

„

,

Printed Name

If you have any questions or problems, please call Kim Kendall at
545-1559 (W) or 586-0570 (H)

:

:

:

:

:

:

.

INITIAL INTERVIEW QUESTIONNAIRE
Date

Name

Interviewer

Subject

//

Age

Length of Cycle

Occupation

Length of Menges

Approx. Income

^

Educational level

General Dietary Habits

Please describe an average day's food intake in detail:
Breakfast

Alcohol (ave/day)

Snack/ tea/coffee

Total Caffeine (ave.

Lunch

Vitamin/mineral Supplement
(describe in detail, include
amounts)

//

cups/day)

Snack /tea/cof f ee

Dinner

Medications/drugs (describe in
detail, include dosages):

Dessert / snack

Cigarettes (ave.

///day)

Menstrual Symptom Typology

When in your cycle do you experience
1.

2.

Menstrual symptoms (include length and onset):
Premenstrual symptoms (include length and onset), peaks? when?
abrupt end?

continued

::

would you describe your menstrual
symptoms?

Primarily mood changes
Mild /mode rate /severe

Depression/anxious/irritable
Other

Primarily physical in nature:
Physical and Mood (BOTH)

How would you describe your premenstrual symptoms?
Primarily mood changes
Mild/moderate/severe
Depress ion /anxious /irr it ab le
Other

Primarily physical in nature:
Physical and Mood (BOTH)

,

:

.
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MOOS

Menstrual

Questionnaire

Form A

Name

Married Status

Age

Number of Children

Today's Date

Occupation

Write the approximate dates of your most recent menstrual
period (flow)
the space marked "A" below.
Then write the dates of the menstrual
period which preceded the most recent one in the space marked
"D"

m

from

other times during
m °st recent cycle

to

week before most
recent flow

most recent flow
from
to

On the next two pages is a list of symptoms which women sometimes experience.
Please describe your experience of each of these symptoms during
the three different time period listed below:
Col.

1

during your most recent menstrual flow (the dates delineated
by area A on the diagram above)

Col.

2

during the one week before your most recent menstrual flow
(area B on the diagram)

Col. 3

during the remainder of your most recent menstrual cycle
(area C)

The answers you put in columns 1, 2, and 3 should be accurage for
Note:
your experience specif icaly during your most recent menstrual cycle.
Please do not simply report your general experience. Also, please report
any experience of these symptoms whether or not they seem to you to be
realted to your menstrual cycle.

Copyright

Rudolf H. Moos, 1968, 1977
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For each answer choose the descriptive
category listed which best
describes your experience of that symptom during
that time. Write
the number of that description in the
space provided.
Even if none of
the descriptions are exactly correct, choose
the ones that best
describe your experience. Do not leave any blank
spaces.

Descriptive Categories:
1

- no experience of symptom

4

-

present, moderate

2

- barely noticeable

5

-

present, strong

3

-

6

- acute or

present, mild

partially disabling

1.

most
recent
flow (A)
1

.

Weight gain

2.

Insomnia

3.

Crying

4.

Lowered school/work performance

5.

Muscle stiffness

6.

Forgetfulness

7.

Confusion

8.

Take naps or stay in bed

9.

Headache

10.

Skin disorders

11.

Loneliness

12.

Feelings of suffocation

13.

Affectionate

14.

Orderliness

15.

Stay home from work/school

16.

Cramps (uterine or pelvic)

17.

Dizziness or faintness

18.

Excitement

19.

Chest pains

20.

Avoid social activities

2

week
before
(B)

3

remainder
of cycle
(C)

98

1

most
recent
flow (A)
21.

Anxiety

22

.

Backache

23

.

Cold sweats

24.

Lowered judgment

25

Fatigue

.

26.

Nausea or vomiting

27.

Re sties sness

28.

Hot flashes

29.

Difficulty in concentration

30.

Painful or tender breasts

31.

Feelings of well-being

32.

Buzzing or ringing in ears

33.

Distractable

34.

Swelling (abdomen/breasts/ankles)

35.

Accidents (cut finger/break dish)

36.

Irritability

37.

General aches and pains

38

Mood swings

.

39.

Heart pounding

40.

Depression (feeling sad/blue)

41.

Decreased efficiency

42.

Lowered motor coordination

43.

Numbness or tingling in hands/feet

44.

Change in eating habits

45.

Tension

46.

Blind spots or fuzzy vision

47.

Bursts of energy or activity

2

week
before
(b)

3

remainder
of cycle
(C)

..

In what ways, if any, was your most recent menstrual cycle unusual?

;
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PREMENSTRUAL ASSESSMENT FORM
(PAF)

Uriel Halbreich, M.D., Jean Endicott

,

Ph.D.,

&

Sybil Schacht

,

M.S.W.*

This form is used to describe changes which may occur during the premenstrual period.

Instructions are on page 2.
Card No:

ID No:

Study No:

Date:

Name or Initials

Education:

(1)

15+ yrs;

(5)

10-12 yrs;

(2)

15 yrs;

(6)

(3)

12-14 yrs; (4)

7-9 yrs; (7)

6

12 yrs

yrs or less

Degrees:

Occupation
(specify title, type of work, size of business, etc.)

Education of husband/mate
(use education code above)

Occupation of husband/mate
(specify)

Average number of days from one menstrual period to the next
days.

days to

If irregular, ranges from

days.

If more than 38

If less than 21 days, reason:

days, reason:
days.

Average duration of premenstrual period
days.

blood flow

Still having menstrual periods:
phase:
3

-

1

- During

Average duration of

1

- No

During premenstrual period,

week after end of blood flow,

Age at first menses:

.

- Yes.

2

-

2

4

If Yes, current

During blood flow,
- Any other

week

Number of children:

Number of miscarriages/abortions:
middle of menstrual cycle)?
Do you have mittelschmerz (ain in the
1

- No

2

- Yes

_
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Special Conditions Du ring Last Three
Menstrual Cycles

Dysmenorrhea (pain when menstruating)

Endometriosis

(diaj; ;nosed

Take birth control pills

by doctor)

:

1-No

:

:

1

l- No

-No

2-Yes (describe)

2-Yes (describe)

2-Yes (specify type, how long

taking)

Have intra-uterine device:

1-No

2-Yes (specify type, how long using)

Use medication/home remedies to "treat" premenstrual changes:
1-No

2-Yes (specify type, reason)

Use any other medications: 1-No

2-Yes (specify type, reason, how long

using)

*New York State Psychiatric Institute and Department of Psychiatry,
College of Physicians and Surgeons, Columbia University, 722 West
168th Street, New York, NY 10032
and New
Supported in part by NIMH Grants No. MH-30907 and MH-23864
York Department of Mental Hygiene.
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Currently pregnant:
Post menopausal:

1-No

1-No

2-Yes (specify)

months

2-Yes (how long)

Not menstruating for other reason:

1-No

Any medical disorder(s) currently present:

years

months

2-Yes (specify reason)

1-No

2-Yes (specify)

The physical, behavioral, and mood changes which
take place during the
premenstrual period may be either positive or negative.
Please focus on the usual changes which have taken place during
your
last three premenstrual periods, even if the changes did not
last
throughout the entire premenstrual period.*

The premenstrual period may range from one to fourteen days. Each woman
should determine the duration of her premenstrual period using these
factors as guides. Physical, behavioral, and mood changes are considered to be part of the premenstrual period if:
they appear or change during the premenstrual period;
they do not exist in the same form or severity immediately
prior to the premenstrual period;
(c) they disappear or return to usual state during the full
flow or menses
(a)
(b)

INSTRUCTIONS

Think about the changes which you experience premenstrually
Consider
each item. Decide whether it describes a new condition or change which
Circle
usually has occurred during your last three premenstrual periods
the appropriate number to indicate the severity of change from your
usual state
.

.

For example, you may be anxious OR, if you are mildly
anxious most of the time, the anxiety may become more
Either type of change should be noted.
severe.

DEFINITIONS OF THE RATINGS OF SEVERITY OF CHANGE FROM USUAL NONPREMEN
STRUAL STATE:
1

- Not applicable, not present at all, or no change from

usual level.

differ from these
*Some studies may have special instructions which

.

.

.
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2

-

Minimal Change (only slightly apparent
to you, other
would probably not be aware of change)

3 -

Mild Change (definitely apparent to you
and perhaps
to others who know you well)

4 -

Moderate Change (clearly apparent to you and/or
others who know you well)

5

- Severe Change (very
apparent to you and/or others who know

you well)

6

-

Extreme Change (the degree of change in severity is so
different from your usual state that it is very
apparent to you OR even people who do not know you well
might notice)

1

- Not

4

- Moderate,

applicable, not present, no change,
5

- Severe,

6

2

- Minimal,

3

- Mild,

- Extreme

Usual Level of Change
During Last 3 Premenrual periods

Changes Present During Premenstrual Period
Have rapid changes in mood (e.g., laughing,
crying, happy, etc.) all within same day ..

Have decreased energy or tend to fatigue easily
Have decreased ability to coordinate fine
movements, poor motor coordination or
clumsiness
Feel anxious or more anxious

Sleep too much or have difficulty getting up
in the morning or from naps

Have a feeling of malaise (i.e., general, nonspecific bad feeling or vague sense of mental
or physical ill-health)
Feel jittery or restless

Have loss of appetite

Have pain, tenderness, enlargement, or swelling
of breasts
Have headaches or migraines
Be more easily distracted (i.e., attention shifts
easily and rapidly)

1

.
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1

- Not

4

-

applicable, not present, no change,

Moderate,

5

-

Severe,

6

-

- Minimal,

2

- Mild,

3

Extreme
Usual Level of Change
During Last 3 Premenstrual periods

Changes Present During Premenstrual Period
Tend to have accidents, fall, cut self,
break things unintentionally

2

3

4

5

6

Have nausea or vomiting

2

3

4

5

6

2

3

4

5

6

Have feelings of weakness

2

3

4

5

6

Feel that you just "can't cope" or are overwhelmed by ordinary demands

2

3

4

5

6

Feel insecure

2

3

4

5

6

2

3

4

5

6

Feel depressed

2

3

4

5

6

Have periods of dizziness, faintness, vertigo,
(room spinning), ringing in the ears, numbness,
tinkling of skin, trembling, lightheadedness ..

2

3

4

5

6

Tend to "nag" or quarrel over unimportant issues.

2

3

4

5

6

Show physical agitation (e.g., fidgeting, hand
wringing, pacing, can't sit still)

,

Have "flare-ups" of allergy, breathing difficulties, stuffy feeling, or watery discharge
from the nose

,

Think of what it would be like to do something
to self, like crash the car, wish to go to
sleep and not wake up, or have thoughts of death
or suicide
Feel less desire to talk or more about (it takes
an effort to do so)

Become more forgetful
Feel dissatisfied with personal appearance

Become more violent with people or things
(e.g., deliberately break things, hit someone)

.,

Take naps during the day or have an overwhelming
desire to do so
Feel sense of unreality, like in a dream,
unreal etc

1

,

Feel pounding of heart or have rapid heartbeat
Get more, enjoyment or excitement out of little
things

1

.
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- Not applicable, not present, no
change,
4 - Moderate,
5 - Severe,
6 - Extreme
1

- Minixnal

2

- Mild

3

,

Usual Level of Change
During Last 3 Premenrual Periods

Changes P resent During Premenstrual
Period
Have difficulty concentrating
Feel confused

Have lowered judgment (i.e., realize
judgment
was less good than usual when looking back
on decision made during premenstrual
period
Feel passive, want others to make decisions,
to take charge, etc

2

3

4

5

6

Have an increased feeling of well being

2

3

4

5

6

Have a lack of self control

2

3

4

5

6

Tend to become more childlike

2

3

4

5

6

Tend to feel or be tearful, weep, or cry

2

3

4

5

6

Feel need to urinate more frequently or have an
increased amount of urine

2

3

4

5

6

Become constipated

2

3

4

5

6

Tend to be self-indulgent in use of time,
spending money, eating, etc

2

3

4

5

6

Have episodes of impulsive behavior

2

3

4

5

6

2

3

4

5

6

Feel under stress

2

3

4

5

6

Pick at, bite or scratch skin, or bite fingernails

2

3

4

5

6

Have mood swings from high to low or low to high

2

3

4

5

6

Tend to become "hysterical" if something
upsets you

2

3

4

5

6

Have guilt feelings

2

3

4

5

6

Feel "empty"

2

3

4

5

6

2

3

4

5

6

Feel sad or blue

2

3

4

5

6

Have tired legs (weak, sore, tremble)

2

3

4

5

6

Tend to smoke more, drink more alcohol or use
"drugs of abuse" (e.g., "pot," "speed," etc)

...

Have outbursts of "irritability" or bad temper

.
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1

- Not

4

-

applicable, not present, no change,

Moderate,

5

- Severe,

6

-

2

- Minimal,

3

- Mild,

Extreme
Usual Level of Change
During Last 3 Premenrual periods.

Changes Present During Premenstrual Periods

Tend to have backaches, joint and muscle
pains or stiffness

2

3

4

5

6

Family or friends know "she is in one of her moods
today"

2

3

4

5

6

Feel "at war" on awakening or have complaints
or outbursts about old irritants

2

3

4

5

6

Act spiteful

2

3

4

5

6

2

3

4

5

6

Urinate less frequently or in lesser amounts

2

3

4

5

6

Have weight gain

2

3

4

5

6

Tend to be intolerant or impatient or to lose
the ability to respond to or understand the
faults, needs or errors of others

2

3

4

5

6

Tend to be overtalkative

2

3

4

5

6

2

3

2

3

2

Feel lonely

,

Have relatively steady abdominal heaviness,
discomfort or pain
Have increased sexual activity or interest
(fantasy, with self, with others)

Have trouble sleeping
Check, if wake early in morning and can't
get back to sleep

Have intermittent pain or cramps in the abdomen

.

Have a decrease in self-esteem (i.e., don't
feel good about self or feel a failure)
Tend to blame others for problems (personal,
at home, work, school, etc.)
effiHave increase in activity, organization,
or
home
at
socially,
involvement
ciency or
work
Tend to brood over unpleasant events
etc
Have skin problems such as acne, pimples,

...

5

6

4

5

6

3

4

5

6

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6
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1

- Not applicable, not present

4

- Moderate,

5

- Severe,

6

,

-

no change,

2

-

Minimal,

3

-

Mild,

Extreme

Changes Present During Premenstrual Periods

Usual Level of Change
During Last 3 Premenstrual Periods

Have edema, swelling, puffiness, or "water
retention"

2

4

5

6

Stay at home more

2

4

5

6

Have less sexual interest or activity (fantasy,
self, others)

2

4

5

6

Tend to avoid social activities

2

4

5

6

Feel bloated

2

4

5

6

Have lowered performance, output, efficiency or
ease in tasks at work, at home, or with
hobbies, etc

Miss time at work because of premenstrual
changes
Want to be alone
Feel a lack of inspiration and creativity

Crave specific foods (sweets, bread, chocolate,
pickles)

Have an increase in appetite or tend to eat
more

2

3

4

5

6

Feel worse in the morning

2

3

4

5

6

Pay less attention to physical appearance

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6

2

3

4

5

6

Feel cold and/or more sensitive to temperature
change

Have bursts of energy or feel more energetic

Become more sensitive to, or intolerant of, personal rejection of self or one's work
Feel more affectionate

Tend to seek advice more often, or about simple
matters
Have pessimistic outlook

Drink more coffee, tea, or cold drinks with
caffeine (cola, rootbeer, etc)
Feel pain or discomfort during intercourse
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1

- Not

4

-

applicable, not present, no change,

Moderate,

5

- Severe,

6

2

- Minimal,

- Mild,

3

- Extreme

Usual Level of Change
During Last 3 Premenstrual Periods.

Changes Present During Premenstrual Period
Do less housework (cleaning, care of
clothes, etc)

1

2

3

4

5

6

Spend less time at leisure activities (hobbies,
TV, reading)

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

Have "flare up" or appearance of cold sores,
diarrhea, belching, spontaneous bruises,
varicose veins, chest pain, hemorrhoids,
numbing, tingling, epilepsy ("fits"), sensitivity of skin to sun (Specify

Have an increase in eye problems or changes
in vision (e.g., sty, redness, watering,
mistiness, discomfort, sensitivity to light)

)

...

In order to obtain a good comparison of your premenstrual state, as compared to your usual state, it would be helpful to have a narrative
description of the differences, if any, between these two times.
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DAILY MOOD FORM
PMS 1982-83
Day of Cycle

Participant
Date

Indicate how you feel today by marking along the line in the plac<
that best describes how you feel today.
Do not spend too much time on
each statement, but give an answer which seems to describe your feelin
best
Be sure to mark all dimensions.
1.

Irritable

Pleased

2.

Outgoing

Withdrawn

3.

Not Lonely

Lonely

4.

Decisive

Indecisive

5.

Tired

Energetic

6.

Distracted

Focused

7.

Valuable

Worthless

8.

Full

Empty

9.

Helpless

Powerful

10.

Sad

Happy

11.

Downhearted

Lightheart

12.

Calm

Tense

13.

Content

Worried

14.

Nervous

Confident

15.

.Ti

t-terv

Relaxed

Please rate how stressful your day has been:
16.

Not al all
stressful

Extremely
stressful

.
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MENSTRUAL DISTRESS QUESTIONNAIRE
Form T
Name

Today's Date
On the next 2 pages is a list of symptoms which women sometimes
experience. For each symptom choose the descriptive category listed
below which best describes your experience of that symptom today.
Circle the number of the category which best describes your experience
of the symptom today
Even if none of the categories is exactly
correct, choose the one that best describes your experience. Please
be sure to circle one number for each symptom. Please also remember
to put your name and the date in the blank spaces at the top of this
page
.

Descriptive Categories:
1.

2.
3.

No reaction at all
Barely noticeable
Present, mild

4.
5.
6.

Present, moderate
Present, strong
Acute or partially disabling

Weight gain

1

2

3

4

5

6

2.

Insomnia

1

2

3

4

5

6

3.

Crying

1

2

3

4

5

6

4.

Lowered school or work performance

1

2

3

4

5

6

5.

Muscle stiffness

1

2

3

4

5

6

6.

Forgetfulness

1

2

3

4

5

6

7

Confusion

1

2

3

4

5

6

8.

Take naps or stay in bed

1

2

3

4

5

6

9

Headache

1

2

3

4

5

6

10.

Skin disorders

1

2

3

4

5

6

11.

Loneliness

1

2

3

4

5

6

12.

Feelings of suffocation

1

2

3

4

5

6

1

2

3

4

5

6

1

.

.

.

13. Affectionate

Orderliness

1

2

3

4

5

6

14.

Stay home from work or school

1

2

3

4

5

6

15.

Cramps (uterine or pelvic)

1

2

3

4

5

6

16.

110

No reaction at all
Barely noticeable
3. Present, mild
1.

4.

2.

5.

17.

Dizziness or faintness

18.

Excitement

19.

Chest pains

6.

Present, moderate
Present, strong
Acute or partially disabling

20. Avoid social activities

21. Anxiety

1

2

3

4

5

6

^

2

3

4

5

5

^

2

3

4

5

6

1

2

3

4

5

6

!

2

3

4

5

6

22. Backache

1

2

3

4

5

6

23. Cold sweats

\

2

3

4

5

6

24. Lowered judgment

1

2

3

4

5

6

25. Fatigue

1

2

3

4

5

6

26. Nausea or vomiting

1

2

3

4

5

6

1

2

3

4

5

6

28. Hot flashes

1

2

3

4

5

6

29. Difficulty in concentration

1

2

3

4

5

6

30. Painful or tender breasts

1

2

3

4

5

6

Feelings of well-being

1

2

3

4

5

6

32. Buzzing or ringing in ears

1

2

3

4

5

6

33. Distractable

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

37. General aches and pains

1

2

3

4

5

6

38. Mood swings

1

2

3

4

5

6

39. Heart pounding

1

2

3

4

5

6

40. Depression (feeling sad or blue)

1

2

3

4

5

6

41. Decreased efficiency

1

2

3

4

5

6

42. Lowered motor coordination

1

2

3

4

5

43. Numbness or tingling in hands or feet

1

2

3

4

5

6

1

2

3

4

5

6

Restlessness

27.

31.

Swelling (e.g., abdomen, breasts, ankles)

34.

35. Accidents

(e.g., cut finger, break dish)

Irritability

36.

44.

Change in eating habits

/c
45

m
Tension
-

.

..123456

46. Blind spots or fuzzy vision

1

2

3

4

5

6

47. Bursts of energy or activity

1

2

3

4

5

6

APPENDIX B
Sample of Post-Study Questionnaire and Follow

Letter Sent to Participants
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POST -STUDY QUESTIONNAIRE

Participant

1.

Keeping self -observation records often has an effect on people's
feelings and behavior. What was your reaction to keeping
records? Did it many any changes in your moods or activities?

2.

Were your menstrual cycles, while you were participating in the
study, typical for you, or different? How different? Which
cycles were different?

3.

Did you make any major changes during the study, or did anything
major happen to you? (moved, married, separated, etc.)

4.

Would you be willing to take part in a similar study again. If
so, what suggestions for changes would you make for the study,
in terms of questionnaires and other procedures.

5.

Did you notice any changes in your feelings or behavior when you
started taking the pills? What were the changes and when did you
experience them?
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FOLLOW-UP LETTER SENT TO PARTICIPANTS

Dear Participant:
The Premenstrual Study research team would like to thank you for
your time and effort which have contributed so greatly to the success
of our project.
The confidential information which you have given us
has been combined with information from other participants. The
meaning of the results of our study is still unclear at this point.
We studied three separate groups of women. Half of each group
received B6 and half received a placebo supplement. Only in the first
group of women did vitamin B6 show a significant effect in lowering
premenstrual depression and increasing concentration. No effects were
seen in the 2nd and 3rd groups of women we studied.
It is possible
that the women in our 2nd and 3rd groups received an expired or less
potent vitamin B6 supplement than those in the 1st group. The vitamin
B6 received by women in groups 2 and 3 is currently being reassayed
for potency and these results are not yet in.

Unfortunately, all of this means that we cannot be sure that vitamin
B6 did have a greater effect than placebo supplements on lowering
premenstrual depression in our study. It seems to have done so in our
1st group and we are currently trying to understand why our results
differed for the 2nd and 3rd groups of women who participated earlier
this year.

Enclosed you will find a check for $12.00 as a small token of our
appreciation for your participation in our project. Also enclosed is
a graph of your individual data on a number of variables which we
measured over 3 menstrual cycles. We have divided each of your 3
cycles into 5 phases and taken an average score for each phase and
plotted this on the graphs which are enclosed. There are 15 points on
each graph, representing 3 months divided into 5 phases each. On the
graph these phases are represented with "M, 2, 3, 4, P
:

menstrual phase

M

-

2

- luteal phase

3

= ovulatory phase

4 =
5 =

follicular phase
premenstrual phase

the scale on each
Each graph represents a different variable and
make comparisons between
graph differs, so that it is not possible to
level of
It is possible to note whether your
two different measures.
varies over the month, or varied
any single measure (i.e., depression)
to the 3rd month <jr tod«Bth
from the 1st month (or baseline period)
Remember that Month 1 (the 1st 5 points
on the vitamin or placebo).

.

,

. .
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on each graph) was baseline only.
The placebo or vitamin was taken
during months 2 and 3 (the 6th - 15th points on
each graph)
Also
remember that it is difficult to understand what
your graphs may mean,
since your scores were affected by many other things
besides the
vitamins or placebos, such as external events, stress,
weather, and
what have you

Most of the labels on the graphs are self-explanatory, but
some
are unclear.
All Neg. Affect

- a combined score of depression and

anxiety
Percv. Stress

= the amount of stress you perceived

in your life each day

Menstr. Pain

= menstrual pain, cramps, backache, etc.

Poor Concen.

= decreased concentration

Autonom. Symp

= autonomic symptoms, such as dizziness,
insomnia, nausea, etc.

H 0 Retent'n,

= water retention, swollen breasts, weight

2

Neg. Aff. Moos

gain, etc.
= Negative affect on the every-other-day

form; includes depression, irritability,
and anxiety

Positive affect on the every-other-day
form; feeling of well-being, affectionate,
excitement, etc.

Pos. Aff. Moos

=

Lack of Cont

= Lack of control

Please write to me at the address below if you have further questions
regarding the study. The final write-up will be available in the
Psychology Department Library (Tobin Hall) later next spring if you are
(Because of the bulk and cost of this write-up,
interested in seeing it.
participants.)
to
be
sent
it will not
Again, we want to thank you very much for your time and patience!
Sincerely

Kim Kendall, M.S.
Director, PMS Research Project
and the PMS Research Team
KK/jb

